Bacterial Vaginosis [BV] knowledge, attitudes, and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: A qualitative study

Bacterial Vaginosis [BV] knowledge, attitudes, and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: A qualitative study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Bacterial Vaginosis [BV] knowledge, attitudes, and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: A qualitative study Cecilia Milford, Buyisiwe L. Dlamini, Nomfuneko A. Mafunda, Timothy S. Hardwick, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7516987/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Dec, 2025 Read the published version in BMC Women's Health → Version 1 posted 13 You are reading this latest preprint version Abstract Background Bacterial vaginosis (BV), the most common cause of vaginitis among reproductive age women ,with, has high recurrence even after treatment. In addition to the physical risks of BV (e.g. increased HIV risk, adverse pregnancy outcomes, preterm birth), the symptoms (malodour, itchiness, vaginal discharge) can cause emotional impacts (e.g. shame, embarrassment, self-consciousness). BV knowledge, attitudes, behavioural change(s) after diagnosis and other previous vaginal health concerns were explored among participants in a clinical trial assessing the safety and biologic effects of a vaginal live biotherapeutic product. Methods In-depth interviews (IDIs) were conducted with female participants in a clinical trial in Boston, USA (n = 14), and Vulindlela, South Africa (SA) (n = 23). Interviews were audio recorded, transcribed and translated. Transcripts were coded and thematically analysed using NVivo. Results Previous BV diagnosis was lower in SA than USA (2(9%) versus 12(86%)), with 7(19%) overall reporting a previous STI. There were five key themes. ( 1 ) Prior BV and other vaginal health experiences – although BV was not frequently diagnosed in SA, participants reported experiencing symptoms (discharge, itchiness and malodour). Conversely, USA participants had experiences with previous BV diagnoses. ( 2 ) Previous health seeking behaviour and treatments – almost all participants from both sites had sought treatment from healthcare professionals for vaginal health concerns, with a few from both sites having used self-care practices. ( 3 ) BV knowledge, attitudes and reactions to diagnosis – BV knowledge in SA was poor compared with the USA, but most participants were relieved to receive help. ( 4 ) Behavioural changes because of BV – vaginal hygiene practices changed- participants washed more frequently/used products to address malodour. Further, BV symptoms resulted in changes in sex acts and/or abstinence. ( 5 ) BV disclosure – varied, with participants commonly disclosing to those who could provide them with support. Conclusions BV knowledge, attitudes and experiences are related to previous diagnosis and treatment. Symptoms impact individuals’ behaviours, regardless of previous diagnosis, and can have psychosocial impacts which need to be addressed via appropriate counselling and treatment strategies. Ongoing research for effective BV prevention, and treatment options that can be made available and accessible to women with BV globally, are needed. Trial registration: South African National Clinical Trials Registry (SANCTR DOH-27-102023-8342; October 27, 2023) and ClinicalTrials.gov (NCT06135974; November 02, 2023). Bacterial vaginosis knowledge and attitudes health seeking behaviour vaginal hygiene USA South Africa qualitative research Background Bacterial vaginosis (BV) is the most common vaginal disorder in women of reproductive age worldwide ( 1 – 4 ). It is a disruption of the vaginal microbiota, where there is a shift from Lactobacilli dominance to a diversity of anaerobic bacteria ( 1 ). Globally, the general population prevalence of BV is high. One systematic review found a BV prevalence of 27% in North America and 25% in Sub-Saharan Africa ( 5 ). A more recent systematic review in pregnant women in Sub-Saharan Africa found a higher prevalence, ranging from 28.5% in Eastern Africa to 52.4% in Southern Africa ( 6 ). In young South African women aged 15–24, a separate estimate for BV prevalence was 42.1% ( 7 ). BV is associated with various adverse health outcomes in those affected, including increased risk of sexually transmitted infections (STIs) and HIV, pelvic inflammatory disease, urogenital infections, abnormal pregnancy/adverse pregnancy outcomes and risk of preterm birth ( 1 , 5 , 8 ). BV experiences range from asymptomatic to increases in vaginal discharge and experiences of vaginal malodour ( 1 , 8 – 10 ). In addition to the physical symptoms of BV, women may experience negative psychosocial impacts which can adversely affect their quality of life ( 4 , 8 , 11 ). These multi-dimensional (physical and emotional) impacts of BV and BV symptoms have led to poor self-esteem, with feelings of shame, embarrassment and self-consciousness in many women ( 8 , 11 ). Further, concerns about malodour have resulted in avoidance of some sexual practices, and even abstinence, affecting relationships between sexual partners ( 8 , 11 ). In addition, fear that others may detect their abnormal odour or discharge ( 12 ) has impacted women’s social and work lives, which can have economic implications. BV is usually treated with antibiotics, such as oral or intravaginal metronidazole and clindamycin ( 4 , 11 ), with varying rates of recurrence after treatment. In the United States of America (USA), people are treated based on diagnostic tests performed in clinics or a laboratory ( 13 ) ( 14 ), while in South Africa syndromic management of vaginal discharge includes BV treatment as part of a treatment package for all potential causes of vaginitis ( 15 ). There are reports of BV recurrence rates of more than 50–69% within 12 months of treatment ( 4 , 16 , 17 ). As a consequence, alternative strategies, such as intravaginal boric acid ( 4 ), and other self-help or traditional methods such as yoghurt or probiotics, have been used by some women to treat their BV ( 3 ). Affected women have attributed their BV acquisition and recurrence to sexual activities in general, including unprotected sex and sex with a new male partner ( 12 , 18 , 19 ). Lifestyle factors, such as stress, have, to a lesser extent, also been attributed to increased risk of BV ( 18 , 20 ). In addition, personal hygiene, such as soaps used to wash the vagina, have been viewed as triggers by women who have BV ( 19 ), resulting in changes in vaginal hygiene practices to manage BV. This manuscript explores the BV related knowledge and attitudes of participants in a clinical trial of a novel vaginal product to reduce recurrent BV (VIBRANT - Vaginal lIve Biotherapeutic RANdomized Trial). In addition, any behavioural change or outcomes experienced by these participants after a BV diagnosis are explored. Furthermore, vaginal health concerns and/or conditions prior to enrolment in the clinical trial, and the relationship between this and participants’ BV knowledge and attitudes during the clinical trial, are explored. Methods Study setting This qualitative study was a sub-study of the VIBRANT study (full title: Vaginal Live Biotherapeutic Randomised Trial: Phase 1 trial of multi-strain Lactobacillus crispatus vaginal live biotherapeutic product (LBP)). VIBRANT was a phase 1 clinical trial that assessed the safety and biologic effects of two LBPs in women with BV (determined by Amsel and/or Nugent score). All participants had BV, were treated with oral metronidazole for seven days, and were then randomised to one of five groups. For all five groups it was required that a vaginal tablet (either placebo or a variation of the LBP) was inserted intravaginally for seven days. The timing and composition of the LBP tablets varied slightly between the trial arms ( 21 ). Both the VIBRANT study and qualitative sub-study were conducted in Boston, Massachusetts in the USA, and Vulindlela, KwaZulu-Natal in South Africa. Boston is a city of approximately 650,000 in a metropolitan area of over 4 million people, and is home to a large number of colleges and universities ( 22 ). The Boston study site was in a private hospital research clinic. Vulindlela is a rural area, consisting largely of isiZulu speaking people, high levels of poverty, poor infrastructure and high HIV prevalence ( 23 ). Healthcare is accessible to community members through public health facilities located in this area. The Vulindlela study site was located in a research centre adjacent to a public health clinic. The VIBRANT study was conducted from February 2024 to February 2025 ( 21 ) and the qualitative sub-study was conducted concurrently from February to December 2024. The overall aim of this qualitative study was to understand and explore the experiences and preferences of women using a vaginally delivered LBP in the clinical trial to inform future product development. One component was to specifically explore knowledge, impact and outcomes of a BV diagnosis, which is the focus of this manuscript. Qualitative sub-study: Population and data collection Qualitative sub-study participants were aged 18–40 years, and were purposively selected from those participating in the VIBRANT study. We aimed to select a representative sample of approximately 15–20 participants per study site (30–40 in total), representing a range of participant ages and product use experience. All of these participants were invited to participate in a series of two in-depth interviews (IDIs) at two different timepoints in the clinical trial – with the first IDI being conducted at, or soon after product use in the clinical trial, and the second IDI being conducted three weeks later, to determine if there had been any changes over time. In addition, we aimed to recruit about 5–10 participants for once-off cases of interest IDIs. These could be done at any time point during the study, and included participants from the VIBRANT study who had note-worthy experiences during their participation in the clinical trial, including challenges with product insertion or adherence, early discontinuation of product, or those who were eligible to participate but chose not to participate. The IDIs had semi-structured interview guides developed specifically for this study (see supplementary files), and explored user experiences, product acceptability, facilitators and barriers to product adherence (and use) and the acceptability of an applicator for product insertion. The knowledge, emotional impact, and behavioural outcomes of a BV-related diagnosis and treatment were also explored. This latter thematic area is the focus of this manuscript. All IDI participants provided separate written or verbal consent to participate in the qualitative sub-study as per requirements of site-specific ethics boards. The IDIs were approximately 1-1.5 hours in duration, and were conducted in a quiet, private venue, at a time that was convenient to the participant. In Vulindlela, South Africa, interviews were conducted in person, and in Boston, USA, they were conducted over an online platform (such as Teams or Zoom) or in person depending on participant preference. Interviews were conducted by interviewers trained both in qualitative research and in sensitive research topics. In South Africa, all interviewers were female, bilingual (first language isiZulu speakers), and all interviews were conducted in isiZulu as preferred by the participants. In the USA, all interviews were conducted in English by a female researcher. The interviews were audio-recorded, with participants’ consent. Demographic and relevant quantitative behavioural data were collected as part of the VIBRANT study’s clinical component; for example, baseline behavioural sexual and reproductive health data, such as BV and sexually transmitted infections (STIs), were collected (see supplementary files for study specific baseline behavioural questionnaire). Data analysis Relevant clinical trial demographic and baseline behavioural data were descriptively analysed using medians, interquartile ranges (IQR), percentages and frequencies in SAS, version 9.4 (SAS Institute Inc). These data were used to describe participants’ sociodemographic characteristics and individual-level BV and STI history. IDIs were transcribed and translated into English (where necessary). Once transcribed, the study team (CM, TSH, BLD, MNM) developed a single code list, based on a review of a representative set of transcripts from both study sites. The code list was informed both by thematic areas arising from the data, as well as through the structure of the IDI guide, which influenced the topics of discussion. This code list was reviewed by a USA team member (NAM) to ensure that it was representative of USA study data. The initial code list was tested on additional transcripts (by CM, TSH, BLD and MNM), and any differences and similarities in interpretation were discussed and the code list was revised. Once agreement was reached, transcripts and the code list were imported into qualitative data analysis software, NVivo version 15 (QSR International), and all transcripts were double coded. Team members met regularly to discuss and compare coding, and to ensure that inter-coder agreements were met throughout the coding process. Once all data were coded, coding reports were generated to create summaries of key codes, and data were organised for a thematic analysis. Thematic areas are described in the results section below. Data triangulation was used to compare findings from the VIBRANT study baseline behavioural questionnaire with IDI findings. Ethical considerations This qualitative sub-study was approved by the Biomedical Research Ethics Committee (BREC) of the University of KwaZulu Natal (BREC/00006221/2023) and the Mass General Brigham (MGB) Institutional Review Board (IRB) (2023P003545). All participants provided written or verbal informed consent to participate in the IDI, with separate consent for audio recording of their IDIs. Consenting was conducted in IsiZulu or English, depending on participant preference. The VIBRANT study received separate ethics approval from BREC (Reference: BREC/5620/2023) and the MGB IRB (2023P001035). Results Ninety-six participants were randomised and enrolled in the VIBRANT study (24 at Boston, USA and 72 at Vulindlela, South Africa). At the Vulindlela site, 20 clinical trial participants participated in two serial IDIs, and 3 completed once-off, cases of interest, IDIs. These cases of interest included one participant who did not use her first study product, one participant who shared her study product with her sister, and one who had challenges with study product insertion. There were no refusals to participate in the serial IDIs in South Africa, but there were 2 participants who refused or were unavailable to participate in cases of interest IDIs. At the Boston site, 12 clinical trial participants completed the first serial IDI and, of these, 10 completed the second serial IDI. One participant did not return for her second IDI, and another was interviewed late for her first IDI, so did not complete a second IDI due to being out of window. The enrolment rate in the VIBRANT study was slow at this site, resulting in a smaller number of enrolled participants. Therefore, recruitment for the IDIs was impacted and, due to a smaller pool of clinical trial participants, a decision was made to reduce the target serial IDI enrolment to at least 10 participants. There were 2 once-off, cases of interest IDIs at this site – one product discontinuer, and one participant who had enrolled but chose not to use the study product. Similarly, due to the smaller number of enrolled VIBRANT study participants, no additional cases of interest were identified. There were no refusals to participate in any IDIs. The median age of IDI participants was 28 years (26 years at Vulindlela, and 31 years at Boston). Of these IDI participants, 38% (n = 14) reported that they had previously been diagnosed with BV and had received BV treatment a median (IQR) of 3 ( 1 – 9 ) times in the past year (Table 1 ). The most commonly reported antibiotics used for treatment of past BV and/or vaginal symptoms were metronidazole, clindamycin and azithromycin, but 46% (n = 17) reported no antibiotic use. Use of other treatments, most commonly vaginal cream, oral probiotics and boric acid, was also reported. Compared to the site in Boston, the site in Vulindlela had lower prevalence of BV diagnosis (86% versus 9%), antibiotic use (79% versus 22%) and other product use (71% versus 26%). Overall, 19% (n = 7) reported having a previous STI diagnosis. Table 1 BV and STI history and treatment Vulindlela (N = 23) Boston (N = 14) Previously diagnosed with BV, % (n) Yes 8.7( 2 ) 85.7( 12 ) Number of times treated in the past year for BV (among those previously diagnosed with BV), median (IQR) 1( 1 – 1 ) 3(2-9.5) Number of times treated for vaginal symptoms in the past year (among those not previously diagnosed with BV), median (IQR) 0(0–1) 0.5(0–1) Previous treatment for vaginal symptoms/ BV Antibiotics used, % (n) Metronidazole 17.4( 4 ) 71.4( 10 ) Clindamycin 0(0) 28.6( 4 ) Tinidazole 0(0) 7.1( 1 ) Azithromycin 13( 3 ) 7.1( 1 ) Doxycycline 4.3( 1 ) 14.3( 2 ) Antibiotic injection 13( 3 ) 0(0) Do not know 17.4( 4 ) 0(0) No antibiotic used 60.9( 14 ) 21.4( 3 ) Other treatments used, % (n) Vaginal cream 21.7( 5 ) 50( 7 ) Home remedies 4.3( 1 ) 7.1( 1 ) Oral probiotics 0(0) 28.6( 4 ) Vaginal probiotics 4.3( 1 ) 7.1( 1 ) Boric acid 0(0) 35.7( 5 ) Other treatment 0(0) 7.1( 1 ) No other treatment 73.9( 17 ) 28.6( 4 ) History of STIs (ever diagnosed), % (n) Gonorrhoea 4.3( 1 ) 14.3( 2 ) Chlamydia 0(0) 35.7( 5 ) Trichomonas 0(0) 7.1( 1 ) Herpes 0(0) 7.1( 1 ) HPV 0(0) 7.1( 1 ) None of the above 52.2( 12 ) 50( 7 ) Don’t know if I had STI 43.5( 10 ) 7.1( 1 ) [Insert Table 1 ] Thematic results Study findings have been thematically organised according to five key themes: 1) prior BV and other vaginal health related experiences; 2) previous vaginal health seeking behaviour/treatments used; 3) BV knowledge, attitudes, and reactions to BV diagnosis; 4) behavioural changes because of BV experiences; 5) vaginal health/hygiene practices because of BV experiences; and 5) BV diagnosis disclosure patterns. Any differences and similarities between sites are highlighted. Prior BV and other vaginal health experiences During the IDIs, none of the participants at the Vulindlela site specifically reported that they had previously been diagnosed with BV (although two did report previous diagnoses during their clinical trial baseline behavioural assessment). However, almost all Vulindlela IDI participants described previous vaginal health concerns – the majority reporting having had experienced a smelly discharge, itchiness or pain during urination, some of which had been diagnosed and treated as STIs. The problem is that itches deep inside where I can't scratch and where I am unable to touch, and if I ever move the flesh, I swell up. (Vulindlela, 36 years) I had something that was coming out, that was some kind of discharge. It was different, it would be brown, and sometimes it would be yellowish, and sometimes it would be white and clean. (Vulindlela, 34 years) It is that my vagina would times have a bad odour. Water [fluid from the vagina] would come out that smells. (Vulindlela, 24 years) Conversely, most IDI participants from Boston reported a previous BV diagnosis. Those who didn’t, made reference to having had BV-related symptoms in the past. Almost all of these participants had experienced multiple recurrences of BV infection, after various treatment options, and were desperate to treat their BV symptoms. I had the BV, and ever since July, I swear to God, it's been BV, yeast, BV, yeast, BV, yeast—back to back to back to back. I've racked up so much money going to my gynaecologist, just with the appointment fees, because they're a specialist—and it really sucks. (Boston, 26 years) After they did the treatment, they did another test, and the test showed that everything is good. Your vagina is happy, but like a month later, the symptoms came back, did another test, and it says, “Yes, your vagina is now mad.” The tests match with my experience, but the treatment, I wouldn't say it didn't help, but it doesn't stay. (Boston, 40 years) In addition, participants from Boston also reported having experienced other vaginal/sexual and reproductive health (SRH) concerns. The majority reported experiencing yeast infections or urinary tract infections (UTI). Endometriosis, polyps in the uterus, and an ovarian cyst were also listed as previous sexual health concerns. I would be prone to yeast infections or UTIs growing up, but I never was officially diagnosed with BV until actually having an IUD [intra-uterine device]. (Boston, 24 years) I've had a polyp, […] recently in the uterus, taken out, and I've had––what do you call it? […] A cyst. I've had a cyst in the ovaries before. (Boston, 38 years) Previous health seeking behaviour and treatments used Almost all participants from both Boston and Vulindlela had sought treatment for previous vaginal health concerns. Many of them described recurrence of symptoms, and repeated treatments required. The majority of participants at Vulindlela had been to the local clinic or a doctor for treatment of vaginal discharge, malodour or itchiness, and had been treated with oral tablets and/or an injection. A few had been provided with vaginal cream to insert and/or apply, and only two described being given a vaginal tablet to insert. Participants did not provide details of the names of the treatment they had used. It would come back at a later stage, this discharge. [….] I would go to the clinic and be given some…some pills. They would give me pills and something else...Ya, last time, I last went last year, even though I don't remember when it was, but they gave me pills and injected me. [….] I was drinking them, it was drinkable pills. [ I Oh, the cream?] No, they have never given me. […] It was drinkable pills then an injection. (Vulindlela, 36 years) I’ve went to the clinic before, they injected me and said I have STIs. I got an injection […]. Only, after that the infection came back again. (Vulindlela, 36 years) [W]hen I had a discomfort, and it was severe. It made me go and see the doctor. [….] Because she gave me a…was it a cream? A vaginal cream, that I inserted at night. It was cream only. (Vulindlela, 34 years) There was…there was… [a tablet that you had to insert in your vagina] [….] It is shaped exactly like the tablet that from here [research site] and its colour. [….] They [local clinic staff] gave me the one that you insert. [….] It treated me well because I got the help. [….] It helped me because what I had got treated, I didn’t have it anymore. (Vulindlela, 24 years) Some participants from Vulindlela described challenges accessing treatment/care from local clinics, largely due to staff attitudes, and preferred to access treatment elsewhere, for example private pharmacies. It’s just that some nurses have tendencies that are not alright. When you come to a nurse because you have a problem, but they will call another one, you see now? “Tell us again, what is wrong with your vagina?” You see, now you are getting embarrassed, [….] You leave the clinic not feeling alright. So, the pharmacy is better. The pharmacy doesn’t ask anything. You get there, you say the problem that you are facing, they get you what will help you and you leave. (Vulindlela, 25 years) Most participants from Boston reported previously being prescribed with antibiotics, such as metronidazole, for their BV symptoms. Some reported taking oral antibiotics, others reported using a cream, or suppositories for treatment. Many of them also described using boric acid to relieve their symptoms. Treatment success was reportedly not high, with many participants reporting using multiple treatment options for recurrent symptoms. I have been trying too many options. The doctor, she just send[s] more antibiotics, more antibiotics, more, more, and then nothing is being helpful. [….] I have been using the boric acid [….] That was working. [….] At least feel better. Yeah, the discharge minimized, and that was helpful. (Boston, 38 years) I feel like in the past when I've used the metronidazole cream, I had very minimal relief, and same with the [vaginal] tablet too. Maybe I've grown a tolerance to both, I don't know, but I feel like the tablet— it was definitely more effective than both. Upon my initial diagnosis, I was prescribed metronidazole tablets, and with that, my symptoms did not change at all. (Boston, 24 years) I did try the boric acid. I've never heard of it until I did a little research, and it said it can help with some symptoms. I tried that maybe earlier this year. I couldn't tell if it helped, really, ‘cause I had some itching at the time and so I tried that. It was okay, but I don't think it was a long-term method which they advertised. It just helps relieve symptoms. I've tried that. Nothing else other than that. (Boston, 29 years) The majority of participants from Boston reported being prescribed medication by their doctors, gynaecologists or primary care physicians. Everything that I know about my vagina is questions I've asked my gynecologist, and I just trust whatever—whatever she says, I trust. (Boston, 26 years) Self-care practices There were also various reports of self-care/self-help practices used by participants from Vulindlela and Boston to treat or alleviate their symptoms. Some Vulindlela participants described steaming or hygiene practices. People just know that if you have a problem there [vagina], you steam using water and onion, done! (Vulindlela, 25 years) [T]here is nothing I did, I would just take water, pour it in the basin and bath to make it [her vagina] cooler because it was painful and inflamed, and when I have washed it with water the pain would decrease, but there is no pill that I can say helped me, no there isn’t. (Vulindlela, 36 years) A couple of participants from Vulindlela reported using citro soda/potassium citrate to alleviate their vaginal malodour, and there were reports of searching online or via social media for remedies. I used to buy citro soda […] I used to drink that thing. […] I learned on TikTok [social media platform name] that it resolves smelly odour, which is what I had, so I used to drink it and it would help me for like two days and will have to do it again and again. (Vulindlela, 20 years) I talk to my friend, the two of us because when she has a problem, she asks me and says, “you know, I am going through such and such”. We usually sit down, and search on google on what could help us. (Vulindlela, 27 years) A few participants from Boston few described scepticism of the healthcare system, which lead to self-help treatment. Some bought over-the-counter treatment, with some reporting using probiotics and one reporting using cannabidiol (CBD) suppositories for BV treatment. In Boston, one participant mentioned that some people would use yoghurt, steam or douche their vaginas as an alternative to accessing the health system. I think people have fraught relationships with the medical system and I think that is part of the reason why, or yeah, I think that's part of the reason why many women have turned to these alternative products that might be harmful, but they're desperate for anything and they don't feel like they can get the help they can within the medical system, unfortunately. People who put yogurt in their vaginas or use steam douching or things like that. (Boston, 25 years) In the past, I've also used CBD repositories. Especially while I was on my period. I heard that that would relax my muscles somehow. I've tried that. (Boston, 24 years) BV knowledge, attitudes and reactions to BV diagnosis No participants from Vulindlela described any knowledge about BV prior to joining the VIBRANT study. Once they joined, they learnt about it and demonstrated varying degrees of understanding of BV. All participants from Boston demonstrated that they understood/had some knowledge about BV. I know that BV is found in almost 25% of the women worldwide. You can see it when you have a white discharge that has a bad odour. It happens sometimes that the vagina might be itchy or have pimples or experience inflammation. […] I didn’t know all that knowledge [before joining the study]. I got it when I was in the study here. (Vulindlela, 19 years) Participants were asked to describe how finding out about their BV status impacted them in their daily lives. This was closely related to their attitudes to BV. The majority of participants from Vulindlela had not previously been diagnosed with BV, and were first diagnosed during participation in the VIBRANT study. Of these, the majority first expressed fear, shock or surprise about their diagnosis. However, this was soon replaced with relief that the BV could be treated during the study. It scared me, I don’t want to lie. I got scared, and I was very shocked that […] I didn’t think that something like this could be found on me. […] I thought that it was a bad thing, yho! I thought it was just a bad thing, shame, and maybe something big, maybe that cannot be cured. […] I learnt about it and they said that it is curable. (Vulindlela, 25 years) A couple of Vulindlela participants had previously suspected that they had a vaginal health issue, and were happy to be diagnosed. Others had no concerns with their diagnosis, although were happy to know about their health status. [W]hen I got here and it [BV] was explained do me, by knowing myself as a woman, I had already seen that there is an infection that I have. (Vulindlela, 34 years) In contrast, the majority of participants from Boston were aware of their BV status before joining the study. They described how the knowledge of having BV was not as impactful as actually experiencing BV. For them, BV was viewed as negative – described as irritating and uncomfortable, impacting daily life, including sex, intimacy and social situations. I'm happy that I can just say, "Oh, yeah, I have BV," and get medication for it. It's 97 cents. It's not expensive. Knowing that I have BV is a non-issue. It's the BV itself which is the issue. [….] I can't have sex easily. When I do have sex, it hurts. Not to mention that just walking around all day—I have all this constant discharge. It's painful, it's burning. It dries up my everything down there, and it smells like hell. The thing is, I take a shower every day. I'm a clean person. I changed my underwear. I've always been a clean person. Now that I have this recurring BV, it makes me feel dirty, because nothing that I do works, and it always smells bad. I can't have sex, and I hate that. I can have sex, but it hurts like hell. (Boston, 26 years) [A]s a woman, ’cause it [BV] makes you feel weird. I guess it's something you can smell, but nobody else can smell, but you think everybody else can smell it. The fishy odour is nasty. […] Especially being a female. You'll be sitting around a group of people, and you're like, “I smell myself. I'm pretty sure everyone else smells it”. (Boston, 38 years) Some Boston participants described that they felt better knowing that there were other people who also had BV and that they were not alone. This had positive implications for their wellbeing. My views [on BV] haven’t changed. What I have learned is, again, I’m not the only one, so don’t feel ashamed or embarrassed. (Boston, 34 years) Behavioural changes because of BV experiences Vaginal health and hygiene practices Some participants at both sites described their vaginal cleaning practices, especially to address their BV symptoms. Some participants from Boston and Vulindlela made use of feminine washes and/or wipes to address malodour and discharge that were experienced from BV. So, when we talk, they [friends] usually ask me, “hey, what makes you not to have a smell?” Then I told them that, “as much as I use GynaGuard [intimate wash soap] when I bath”. I told them they must use it. (Vulindlela, 27 years) I’ll use feminine washes. Feminine washes, detox pearls, boric acid. That’s as far as it goes. (Boston, 28 years) Other participants described avoiding use of soap or using gentle soap to clean their vaginas. “Ay me, I bath with water”. I just bath, then I use cold water to wash my vagina. (Vulindlela, 20 years) I try to avoid getting soap anywhere near the inside. I try to keep it as far from the outside as I can, or on the outside. (Boston, 24 years) Frequency of washing varied between individuals, from 1 to 3 or 4 times per day. I usually washed in the morning, and I would wash again when I was going to bed. (Vulindlela, 27 years) I shower in the morning, and I shower after the gym, and then sometimes I shower at night, depending if I go out. (Boston, 40 years) A few Vulindlela participants reported changes in their hygiene practices after their BV diagnosis during the study. [B]efore I came, when I had the, the discharge that was coming out with a smell, I ended up trying to buy wipes, you see? […] But when I got here [research centre], we were told, “For now, can you stop using soap”. I would then just bath my body then take something to get water and clean it with cold water. (Vulindlela, 34 years) They taught me that as I still have BV, [….] when I was cleaning the private part, I must not insert a finger, because the finger has germs. (Vulindlela, 24 years) Similar to Vulindlela, some Boston participants changed their vaginal hygiene practices during the study, including showering/cleaning more regularly. As far as instead of two showers a day, it would be three showers a day type thing. (Boston, 33 years) Changing clothes/laundry practices In addition, Boston participants reported that they had to change their underwear more regularly or do laundry more often because of the associated discharge and odour of BV. It comes with strong odour, discharge. Uncomfortable, I have to change my underwear twice to three times a day sometimes. (Boston, 32 years) I get wet because the discharge is mostly liquid. It's mostly uncomfortable. I need to change my panties and my panty liners frequently. Sometimes, I don't know this is me, but I can smell it. All of that. (Boston, 38 years) Changes to sexual behaviour/practices Changes to sexual practices as a result of BV diagnosis were not discussed at Vulindlela. This is possibly because participants were first diagnosed with BV during the study, therefore there was no previous real life experience to draw on. However, one participant reported that because of her BV, she was advised to use a condom during sex. They taught me that as I still have BV, I have to use a condom when I have sex. (Vulindlela, 24 years) Participants from Boston reported more changes in sexual behaviour as a result of BV – some reported abstaining, and others reported reducing the amount of sex or changing sex acts (e.g. no more oral sex). These changes were made because of being self-conscious about the BV related malodour, because of discomfort during sex, and their perceived impact of sex on the recurrence of BV symptoms. Yeah, the symptoms are very––it affects your life a lot. I'm not gonna have sex with someone when it smells bad. Yeah, it makes me very uncomfortable, very self-conscious. Yeah, it made me feel kind of gross. (Boston, 40 years) Oral [sex] had already been impossible 'cause I'd been having recurrent BV, and that recurrent like smell and discharge. (Boston, 26 years) BV diagnosis disclosure patterns Only some participants from Vulindlela and Boston disclosed their BV status to others. Participants from Vulindlela were more likely to disclose to female family members (mothers, sisters, grandmothers and/or aunts), whereas participants from Boston were more likely to disclose to their partners. Although, there were a few participants from Vulindlela who did disclose their BV diagnosis to their partners, and a few from Boston who did tell female family members about their BV. The level of detail disclosed also varied between participants. I just thought, okay, I will tell my mother, even though I will not tell her every single thing, but I will tell her that there is this kind of a pill, and they say that it treats the BV disease. Even though I will not tell her deeply about what it is. (Vulindlela, 19 years) [S]o my partner's actually in medical school [laughs], so actually it's helpful. I think with my partner, I'm pretty much completely transparent about all aspects of it [BV]. With my mom, I think I was—maybe I didn't need to be this honest, but I basically told her the reason, I was like, "I think this happened is because I had sex without a condom." She was like, "Oh my god." (Boston, 25 years) A few participants also disclosed to friends. Some participants reportedly disclosed their BV status for altruistic reasons, as they wanted others to get information and help for BV if necessary. I used to tell others too because some people don’t know about the illness called BV, which comes out of a person’s private part, of a woman. (Vulindlela, 20 years) I feel like dealing with this condition since the end of last year has very clearly impacted my life, and so I feel like if I'm catching up with a friend and they're like, "How are you doing?" I'm like, "Well, I've been dealing with some health stuff." Then very naturally, they're like, "Oh, what kind of health stuff [laughs]?" I'm like, "Okay, well there's this thing called BV." I think in general, yeah, I've just been—I've tried to be open about it because I think part of the reason why conditions like this aren't studied is because people are hush hush about it because it is extremely embarrassing and stigmatizing, but I think openness is probably better than not openness. (Boston, 25 years) Participants had varying reasons for disclosing to some and not to other people, as described by one Vulindlela participant: It was only my Mother, it was my Mother and my sister who knew. [….] I didn’t tell my partner. [I [F]riends, have you ever told your friends?] [….] Oh, what made me to tell my friends is because, isn’t it we are all on family planning, so I thought maybe they could also be able to come here [to the research centre] … to get this research that is about BV. Maybe they can also get helped as I also got helped. What made me not to tell my partner is because he was going to judge me. He likes to be judgemental. (Vulindlela, 25 years) Some people did not disclose their BV status at all: I don't share with people. Not too much because it's a study product, but because it's bacterial vaginosis. No one wants to talk about that. If it was a study product for any other—if it was for throat pain, I would happily share it with the world, but no[one] needs to know I have BV. (Boston, 40 years) Discussion Similar to previous research, women in this study had poor levels of awareness of or knowledge about BV prior to being diagnosed with it ( 3 ). In this study, few South African participants had previously been diagnosed with BV, compared with the USA participants, who had mostly had a previous BV diagnosis. As a result, most USA participants demonstrated a good knowledge of BV, whereas South African participants had limited knowledge or awareness before their participation in the VIBRANT study. However, participants from both countries reported similar past SRH and vaginal health experiences – including increased vaginal discharge and malodour, typical of BV ( 1 , 8 – 10 ), as well as recurrence of these symptoms after treatment. In South Africa, the standard treatment guidelines for primary health care, recommend that STIs are syndromically managed in order to be able to treat more than one condition that could be occurring at the same time ( 15 ). Furthermore, this is exacerbated by limited resources in some health care settings. However, this practice of treating symptoms rather than testing for STIs or BV specially, could be the reason for limited previous diagnosis in South African participants. Participants in this qualitative study described various treatment strategies and drug formulations accessed for their vaginal health conditions or BV symptoms, prior to their participation in the VIBRANT study ( 21 ). These included oral tablets, injections, vaginal creams, and vaginal inserts/tablets. Specifically, antibiotics such as metronidazole, were reported by USA participants as recommended for BV treatment ( 4 , 11 ). However, attitudes of healthcare workers and reduced faith in treatment because of recurrence of symptoms resulted in participants reporting trying self-care treatment strategies. This move to alternative, self-help treatment strategies including using boric acid, douching, probiotics and yoghurt has also been reported elsewhere ( 3 , 4 ). In South Africa, where there is a strong reliance on traditional healing in some cultures, it is surprising that participants did not describe accessing these services. However, there were reports of vaginal steaming and douching by a few South African participants. In this study, participants who reported previous BV diagnosis described how their BV symptoms, malodour and vaginal discharge, as well as the concern that sex could trigger BV, had impacted their sexual behaviours – including abstinence and reducing frequency of sex. Previous research describes that decreased sexual quality of life can also result in depression, distress and relationship disruptions ( 10 ). Furthermore, participants in this study demonstrated shame and embarrassment as a result of BV symptoms. These negative psychosocial impacts of BV can result in reducing quality of life ( 4 , 8 , 11 ). However, participants in this study revealed that knowing that others suffered from BV made them feel less ashamed, which had positive implications for their wellbeing. Experiences of BV also resulted in participants reporting changes in their vaginal hygiene and/or washing practices, both to decrease symptoms as well as to reduce potential for BV recurrence. Initially, participants described more frequent washing, and the use of feminine washes or wipes to address malodour and discharge. However, as highlighted elsewhere, soaps used to wash the vagina have been viewed as triggers for BV ( 19 ), and use of soap free washes have been reported for vaginal hygiene ( 12 ). Similarly, some participants in this study described avoiding soap or using gentle soaps to clean their vaginas after BV diagnosis. In addition, USA participants in this study described frequently changing their underwear, or more frequently washing their clothes because of the increased vaginal discharge and malodour of BV. Women in other research also report changing their underwear more frequently ( 12 ), or choosing clothing accordingly – choosing cotton underwear, avoiding tight clothing, and wearing clothing that encourages ventilation to manage their BV symptoms ( 11 , 12 ). South African participants were more likely to disclose their BV diagnosis to female family members and USA participants were more likely to disclose to their male sexual partners. South African participants often lived with other female family members, and this could have impacted on their decisions to tell them. Although USA participants did not always live with their male partners, many were in committed relationships. Other studies have demonstrated that disclosure to certain people is often related to the need for encouragement and support ( 8 , 11 ). Some participants at both sites disclosed to their friends, and this was often altruistic in nature – where they wanted to provide information and guidance to others who may also experience BV. Previous research found that single women were less likely to discuss their BV diagnosis with casual partners and more likely to discuss it with friends, whereas women in relationships were more likely to discuss their concerns with regular partners, but also commonly discussed their diagnosis with friends as a means of information gathering ( 8 ). By disclosing to partners, women have been able to get support with managing symptoms in intimate exchange/sexual encounters ( 11 ). Future recommendations This research highlights the lack of adequate diagnosis and treatment of BV in the healthcare setting, especially in the South African population. There is a need for healthcare staff to learn to differentiate BV from other conditions, and to treat it appropriately ( 11 ). Healthcare provider training on BV identification and management in resource constrained settings, where syndromic management of STIs is recommended ( 15 ) could facilitate further identification and appropriate management of BV. Further studies are required to be able to identify strategies to treat BV so that there is minimal recurrence ( 21 ). Healthcare providers have an obligation to provide clients with better BV related information, knowledge and support ( 10 , 12 ). The benefits of medical versus self-care treatment strategies need to be understood, and awareness and education should also target this. Education and support need to extend beyond the healthcare setting, creating increased awareness of BV, with targeted advertising campaigns and education in schools and communities around SRH and BV ( 12 ). With improved public knowledge, stigma and psychosocial impacts of BV can be better managed and supported. In order to assess the burden of BV, more quantitative studies can be conducted to explore the impact of/association of BV with emotional, sexual and social health ( 10 ). Through this, targeted support can be provided to people who are diagnosed with BV. Appropriate diagnosis and treatment and support are critical to ensure that BV is adequately managed and that quality of life and associated stigma and health risks of BV are eliminated. Limitations As with any study, there are some limitations. Due to the qualitative nature of the study, the findings are limited in generalisability, but are exploratory in nature. Although there are some differences between the USA and South African participants’ reports, these may be specific to the regions in which the study was conducted. However, there are some findings which are more general, and which highlight some of the important challenges with BV knowledge and treatment experiences, which are useful for future research and education on BV. Conclusions BV knowledge, attitudes and experiences are related to previous diagnosis and treatment. However, experiences of symptoms impact individuals’ behaviours, regardless of previous diagnosis. Experiences of discharge, malodour and discomfort all have psychosocial impacts which cannot be appropriately addressed without access to appropriate counselling and treatment options. There is a need to ensure that there is ongoing research for effective BV prevention and treatment options that can be made available and accessible to women with BV globally. Abbreviations BREC: Biomedical Research Ethics Committee BV: Bacterial vaginosis CBD: Cannabidiol HIV: Human immunodeficiency virus IDI: In-depth interview IQR: Interquartile range IRB: Institutional Review Board IUD: Intra-uterine device LBP: Live biotherapeutic product MGB: Mass General Brigham SRH: Sexual and reproductive health STI: Sexually transmitted infection USA: United States of America UTI: Urinary tract infection VIBRANT: Vaginal lIve Biotherapeutic RANdomized Trial Declarations Funding: This work was funded by the Gates Foundation under under INV-037901 and INV-037902. Conflict of interest: The authors CM, BLD, NAM, TSH, LL, AAK, MNM and DP declare that they have no conflict of interest. Dr. Mitchell has served as a consultant for Freya Biosciences, Concerto Biosciences and Ancilia Biosciences. Dr. Mitchell has a financial interest in Ancilia Biosciences, a company developing a new class of Live Biotherapeutics and other bacterial products. Dr. Mitchell’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies. Ethics approval: Ethics approval was obtained from the Biomedical Research Ethics Committee (BREC) of the University of KwaZulu Natal (BREC/00006221/2023) and the Mass General Brigham (MGB) Institutional Review Board (IRB) (2023P003545). Consent to participate: All participants provided written or verbal informed consent to participate in the IDI, with separate consent for audio recording of their IDIs. Consent for publication: Not applicable, individual data/images not used. Availability of data and material: Access to the data from this sub-study may be requested through submission of a research concept to the corresponding author at [email protected] . The concept must include the research question, data requested, analytic methods, and steps taken to ensure ethical use of the data. Access will be granted if the concept is evaluated to have scientific merit and if sufficient data protections are in place. Authors contributions: CM, CMM and DP contributed to the study conception and design. Data collection was conducted by BLD, MNM, NAM and AK. Qualitative data analysis was performed by CM, BLD, MNM and TSH. Quantitative data analysis was conducted by LL. The first draft of the manuscript was written by CM. All authors provided input to the draft, and read and approved the final manuscript. Acknowledgements: This study was funded by the Gates Foundation (INV-037901 and INV-037902). The authors would like to thank the participants for their time for participating in this study. References Abou Chacra L, Fenollar F, Diop K. Bacterial Vaginosis: What Do We Currently Know? Frontiers in Cellular and Infection Microbiology. 2022;11:672429. Woodman Z. Can one size fit all? Approach to bacterial vaginosis in sub-Saharan Africa. Annals of Clinical Microbiology and Antimicrobials. 2016;15:16. Bilardi J, Walker S, McNair R, Mooney-Somers J, Temple-Smith M, Bellhouse C, et al. Women's Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. PLoS One. 2016;11(3):e0151794. Chow K, Wooten D, Annepally S, Burke L, Edi R, Morris SR. Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments. BMC Womens Health. 2023;23(1):112. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sexually Transmitted Diseases. 2019;46(5):304–11. Nyemba DC, Haddison EC, Wang C, Johnson LF, Myer L, Davey DJ. Prevalence of curable STIs and bacterial vaginosis during pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. Sexually Transmitted Infections. 2022;98(7):484–91. Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(2):e1002511. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013;8(9):e74378. Brusselmans J. The emotional, sexual and social impact of (recurrent) Bacterial Vaginosis: A systematic review: University of Ghent; 2020. Brusselmans J, De Sutter A, Devleesschauwer B, Verstraelen H, Cools P. Scoping review of the association between bacterial vaginosis and emotional, sexual and social health. BMC Womens Health. 2023;23(1):168. Adolfsson A, Hagander A, Mahjoubipour F, Larsson P-G. How Vaginal Infections Impact Women’s Everyday Life —Women’s Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis. Advances in Sexual Medicine. 2017;07(01):1–19. Bilardi J, Walker S, Mooney-Somers J, Temple-Smith M, McNair R, Bellhouse C, et al. Women's Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated with Recurrence. PLoS One. 2016;11(3):e0150272. CDC. Sexually transmitted infections treatment guidelines, 2021. 2021. https://www.cdc.gov/std/treatment-guidelines/default.htm. Accessed 01 Sep 2025. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. Morbidity and Mortality Weekly Report, Recomm Rep. 2021;70(No. RR-4):1–187. National Department of Health (NDoH), Essential Drugs Programme. Primary Healthcare Standard Treatment Guideline and Essential Medicine List. South Africa; 2024. https://www.health.gov.za/nhi-edp-stgs-eml/. Accessed 25 Aug 2025. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with Recurrence. Journal of Infectious Diseases. 2006;193(11):1478–86. Muzny CA KP. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sexually Transmitted Diseases. 2020;47(7):441–6. Bilardi JE, Walker SM, Temple-Smith MJ, McNair RP, Mooney-Somers J, Vodstrcil LA, et al. Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis. PLoS One. 2017;12(3):e0173637. Anstey Watkins J, Ross JDC, Thandi S, Brittain C, Kai J, Griffiths F. Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. PLoS One. 2019;14(11):e0224964. Nansel TR, Riggs MA, Yu K-F, Andrews WW, Schwebke JR, Klebanoff MA. The association of psychosocial stress and bacterial vaginosis in a longitudinal cohort. American Journal of Obstetrics and Gynecology. 2006;194(2):381–7. Chetty C, Mafunda NA, Happel AU, Khan A, Demidkina BC, Yende-Zuma N, et al. Randomized Trial of Multi-Strain Lactobacillus crispatus Vaginal Live Biotherapeutic Products after Antibiotic Therapy for Bacterial Vaginosis: Study Protocol for VIBRANT (Vaginal Live Biotherapeutic RANdomized Trial). Preprint. 2025. Deloitte, Datawheel. Data USA: Boston, MA. 2025. https://datausa.io/profile/geo/boston-ma/. Accessed 02 Sep 2025. George G, Beckett S, Cawood C, Khanyile D, Govender K, Kharsany AB. Impact of HIV testing and treatment services on risky sexual behaviour in the uMgungundlovu District, KwaZulu-Natal, South Africa: a cross-sectional study. AIDS Research and Therapy. 2019;16:20. Additional Declarations Competing interest reported. The authors CM, BLD, NAM, TSH, LL, AAK, MNM and DP declare that they have no conflict of interest. Dr. Mitchell has served as a consultant for Freya Biosciences, Concerto Biosciences and Ancilia Biosciences. Dr. Mitchell has a financial interest in Ancilia Biosciences, a company developing a new class of Live Biotherapeutics and other bacterial products. Dr. Mitchell’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies. Supplementary Files VMRCSpecialcaseOtherIDIguidev1.026Oct2023Approved.pdf VMRCSpecialcaseDiscontinuerIDIguidev1.026Oct2023Approved.pdf VMRCSpecialcaseNonparticipantsIDIguidev1.026Oct2023Approved.pdf VMRCSerialIDIguidev1.026Oct2023Approved.pdf VIBRANTEnrollmentbaselinebehaviourCRF.pdf Cite Share Download PDF Status: Published Journal Publication published 12 Dec, 2025 Read the published version in BMC Women's Health → Version 1 posted Editorial decision: Revision requested 13 Oct, 2025 Reviews received at journal 13 Oct, 2025 Reviewers agreed at journal 13 Oct, 2025 Reviews received at journal 12 Oct, 2025 Reviewers agreed at journal 07 Oct, 2025 Reviewers agreed at journal 05 Oct, 2025 Reviewers agreed at journal 02 Oct, 2025 Reviewers agreed at journal 30 Sep, 2025 Reviewers invited by journal 29 Sep, 2025 Editor assigned by journal 29 Sep, 2025 Editor invited by journal 09 Sep, 2025 Submission checks completed at journal 04 Sep, 2025 First submitted to journal 04 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7516987","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":527303308,"identity":"205491fb-1f9e-43ab-9bec-f9c790f50b3c","order_by":0,"name":"Cecilia Milford","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+UlEQVRIiWNgGAWjYJCCAw8MgCQzc8MHICkHESGkJQGshbFxBpA0hogQsgaiAKIlsQEhgh3wtzc/PJBQYMeg287Y2PBxj3X6/LDDQBEGOzndBuxaJM4cMwA6LJnB7DBjY+OMZ+m5G2+nAUUYko3NDmDXYiCRA/ILM0hL+2OeA4dzN85OAGk5kLgNlxb5NyAt9WBbmoFa0g1np3/Ar0WCB6TlMFxLgrx0Dn5bJM6AXG5wnAfilwPphhukcwpAvsPpF/72w48/fPhTLWd2/vDBhg8HrOXlZ6dv/vChwk4OlxYY4EE4FazSAL9yVCDfQIrqUTAKRsEoGAkAAINrZo0b229jAAAAAElFTkSuQmCC","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":true,"prefix":"","firstName":"Cecilia","middleName":"","lastName":"Milford","suffix":""},{"id":527303310,"identity":"1d5d7809-79bd-4485-a2ea-e90d11738647","order_by":1,"name":"Buyisiwe L. Dlamini","email":"","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":false,"prefix":"","firstName":"Buyisiwe","middleName":"L.","lastName":"Dlamini","suffix":""},{"id":527303312,"identity":"f0f8e0e2-ea52-4127-abcc-876099ae9acb","order_by":2,"name":"Nomfuneko A. Mafunda","email":"","orcid":"","institution":"Vincent Center for Reproductive Biology","correspondingAuthor":false,"prefix":"","firstName":"Nomfuneko","middleName":"A.","lastName":"Mafunda","suffix":""},{"id":527303314,"identity":"e6f25bef-ec02-49a4-99e4-7c0950623336","order_by":3,"name":"Timothy S. Hardwick","email":"","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":false,"prefix":"","firstName":"Timothy","middleName":"S.","lastName":"Hardwick","suffix":""},{"id":527303316,"identity":"5aab2637-20a7-4a7c-819b-f6865c0bad6a","order_by":4,"name":"Lara Lewis","email":"","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":false,"prefix":"","firstName":"Lara","middleName":"","lastName":"Lewis","suffix":""},{"id":527303317,"identity":"de550160-aef2-465c-8d73-0b69de830e18","order_by":5,"name":"Anam A. Khan","email":"","orcid":"","institution":"Vincent Center for Reproductive Biology","correspondingAuthor":false,"prefix":"","firstName":"Anam","middleName":"A.","lastName":"Khan","suffix":""},{"id":527303319,"identity":"f73bb8ac-d08e-4a9b-8b82-06ad22488285","order_by":6,"name":"Makhosazane N. Mdladla","email":"","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":false,"prefix":"","firstName":"Makhosazane","middleName":"N.","lastName":"Mdladla","suffix":""},{"id":527303322,"identity":"6c4f309b-a3b5-4138-8cba-eb09ade013a2","order_by":7,"name":"Caroline M. Mitchell","email":"","orcid":"","institution":"Vincent Center for Reproductive Biology","correspondingAuthor":false,"prefix":"","firstName":"Caroline","middleName":"M.","lastName":"Mitchell","suffix":""},{"id":527303325,"identity":"cfe22e12-4f77-41bb-834b-67929460a5ff","order_by":8,"name":"Disebo Potloane","email":"","orcid":"","institution":"Centre for the AIDS Programme of Research in South Africa","correspondingAuthor":false,"prefix":"","firstName":"Disebo","middleName":"","lastName":"Potloane","suffix":""}],"badges":[],"createdAt":"2025-09-02 11:08:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7516987/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7516987/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12905-025-04210-3","type":"published","date":"2025-12-12T15:59:29+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":93274735,"identity":"732ef99b-2f03-4abb-9f2b-9dd809f79158","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":141838,"visible":true,"origin":"","legend":"","description":"","filename":"BVmanuscript05Sep2025final.docx","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/894cdf19730a04eab9da0401.docx"},{"id":93274734,"identity":"bd481fb9-2d5f-4c8d-a578-2f9d5d27b3d3","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":11867,"visible":true,"origin":"","legend":"","description":"","filename":"c613f83af72a41148eeb6e9b1cd690fa.json","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/71332ccacca17214b891e973.json"},{"id":93275054,"identity":"5f723418-8107-4695-87fd-56fc44c3dcde","added_by":"auto","created_at":"2025-10-11 01:57:28","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":656973,"visible":true,"origin":"","legend":"","description":"","filename":"VIBRANTEnrollmentbaselinebehaviourCRF.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/d7f8eacaf7b3744b80ab6f8d.pdf"},{"id":93274737,"identity":"15493ebd-02c5-4f37-ace4-731f9db6d4c1","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":256645,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSerialIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/16585d324ca7dfe9d19503a8.pdf"},{"id":93274744,"identity":"9a448af6-e853-4c3a-9ed7-d7ac8522e569","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":232852,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseDiscontinuerIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/2f4863c2cb8c805fe2dfd833.pdf"},{"id":93274742,"identity":"58180ac9-f312-478e-bd2c-dce86d9a6b72","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":216820,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseNonparticipantsIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/7f727f810fcbeafcaa71f0e8.pdf"},{"id":93275097,"identity":"1d64ec0a-ead4-4386-b0e6-20220b980130","added_by":"auto","created_at":"2025-10-11 02:05:29","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":230484,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseOtherIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/3d8a39135537897b10c63526.pdf"},{"id":93274747,"identity":"e3a5e84b-aa50-49ce-9c4b-9b62d11a7a21","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"xml","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":121568,"visible":true,"origin":"","legend":"","description":"","filename":"c613f83af72a41148eeb6e9b1cd690fa1enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/871fc2a4d4be7a572dd2973a.xml"},{"id":93274745,"identity":"22347e5e-a0fd-408e-8feb-d33241da8a46","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"xml","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":110903,"visible":true,"origin":"","legend":"","description":"","filename":"c613f83af72a41148eeb6e9b1cd690fa1structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/5ccd9705a5f3cb81dfb677d1.xml"},{"id":93275055,"identity":"6937ae16-0a1a-4eda-bab7-6b1e6cffa249","added_by":"auto","created_at":"2025-10-11 01:57:28","extension":"html","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":134197,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/9a33401211f2ed64234359e8.html"},{"id":98244105,"identity":"0fe0d1df-9ea9-45c3-941c-de18c35c127a","added_by":"auto","created_at":"2025-12-15 16:13:03","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1105342,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/38a89727-3b93-4302-a400-42de3401c7f2.pdf"},{"id":93274736,"identity":"eda18f24-e765-460c-9a46-a66d1fc23456","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":230484,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseOtherIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/61ce5f82f3ef96e862791eff.pdf"},{"id":93275057,"identity":"b7c6aa49-7b96-4533-98a7-96146a205e18","added_by":"auto","created_at":"2025-10-11 01:57:30","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":232852,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseDiscontinuerIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/26a10bf1c729c1f2e8a39f2e.pdf"},{"id":93274738,"identity":"6ea55f96-e12c-4180-9fc4-8987aca619dc","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":216820,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSpecialcaseNonparticipantsIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/ddfe778e393c9d18af615f2e.pdf"},{"id":93274741,"identity":"8f073816-1066-41c4-91dc-27dda68c5af1","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":256645,"visible":true,"origin":"","legend":"","description":"","filename":"VMRCSerialIDIguidev1.026Oct2023Approved.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/7870ff5e9be2f4fe1a7bd2dd.pdf"},{"id":93274743,"identity":"12be5cf8-3cc3-4706-8ed2-3ac59db2eaf0","added_by":"auto","created_at":"2025-10-11 01:49:28","extension":"pdf","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":656973,"visible":true,"origin":"","legend":"","description":"","filename":"VIBRANTEnrollmentbaselinebehaviourCRF.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7516987/v1/a8fae95d907ceb6e441d836d.pdf"}],"financialInterests":"Competing interest reported. The authors CM, BLD, NAM, TSH, LL, AAK, MNM and DP declare that they have no conflict of interest. Dr. Mitchell has served as a consultant for Freya Biosciences, Concerto Biosciences and Ancilia Biosciences. Dr. Mitchell has a financial interest in Ancilia Biosciences, a company developing a new class of Live Biotherapeutics and other bacterial products. Dr. Mitchell’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies.","formattedTitle":"Bacterial Vaginosis [BV] knowledge, attitudes, and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: A qualitative study","fulltext":[{"header":"Background","content":"\u003cp\u003eBacterial vaginosis (BV) is the most common vaginal disorder in women of reproductive age worldwide (\u003cspan additionalcitationids=\"CR2 CR3\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). It is a disruption of the vaginal microbiota, where there is a shift from \u003cem\u003eLactobacilli\u003c/em\u003e dominance to a diversity of anaerobic bacteria (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Globally, the general population prevalence of BV is high. One systematic review found a BV prevalence of 27% in North America and 25% in Sub-Saharan Africa (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). A more recent systematic review in pregnant women in Sub-Saharan Africa found a higher prevalence, ranging from 28.5% in Eastern Africa to 52.4% in Southern Africa (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). In young South African women aged 15\u0026ndash;24, a separate estimate for BV prevalence was 42.1% (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eBV is associated with various adverse health outcomes in those affected, including increased risk of sexually transmitted infections (STIs) and HIV, pelvic inflammatory disease, urogenital infections, abnormal pregnancy/adverse pregnancy outcomes and risk of preterm birth (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). BV experiences range from asymptomatic to increases in vaginal discharge and experiences of vaginal malodour (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eIn addition to the physical symptoms of BV, women may experience negative psychosocial impacts which can adversely affect their quality of life (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). These multi-dimensional (physical and emotional) impacts of BV and BV symptoms have led to poor self-esteem, with feelings of shame, embarrassment and self-consciousness in many women (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). Further, concerns about malodour have resulted in avoidance of some sexual practices, and even abstinence, affecting relationships between sexual partners (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). In addition, fear that others may detect their abnormal odour or discharge (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e) has impacted women\u0026rsquo;s social and work lives, which can have economic implications.\u003c/p\u003e\u003cp\u003eBV is usually treated with antibiotics, such as oral or intravaginal metronidazole and clindamycin (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e), with varying rates of recurrence after treatment. In the United States of America (USA), people are treated based on diagnostic tests performed in clinics or a laboratory (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e) (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e), while in South Africa syndromic management of vaginal discharge includes BV treatment as part of a treatment package for all potential causes of vaginitis (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). There are reports of BV recurrence rates of more than 50\u0026ndash;69% within 12 months of treatment (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). As a consequence, alternative strategies, such as intravaginal boric acid (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e), and other self-help or traditional methods such as yoghurt or probiotics, have been used by some women to treat their BV (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eAffected women have attributed their BV acquisition and recurrence to sexual activities in general, including unprotected sex and sex with a new male partner (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). Lifestyle factors, such as stress, have, to a lesser extent, also been attributed to increased risk of BV (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). In addition, personal hygiene, such as soaps used to wash the vagina, have been viewed as triggers by women who have BV (\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e), resulting in changes in vaginal hygiene practices to manage BV.\u003c/p\u003e\u003cp\u003eThis manuscript explores the BV related knowledge and attitudes of participants in a clinical trial of a novel vaginal product to reduce recurrent BV (VIBRANT - Vaginal lIve Biotherapeutic RANdomized Trial). In addition, any behavioural change or outcomes experienced by these participants after a BV diagnosis are explored. Furthermore, vaginal health concerns and/or conditions prior to enrolment in the clinical trial, and the relationship between this and participants\u0026rsquo; BV knowledge and attitudes during the clinical trial, are explored.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eStudy setting\u003c/h2\u003e\u003cp\u003eThis qualitative study was a sub-study of the VIBRANT study (full title: Vaginal Live Biotherapeutic Randomised Trial: Phase 1 trial of multi-strain \u003cem\u003eLactobacillus crispatus\u003c/em\u003e vaginal live biotherapeutic product (LBP)). VIBRANT was a phase 1 clinical trial that assessed the safety and biologic effects of two LBPs in women with BV (determined by Amsel and/or Nugent score). All participants had BV, were treated with oral metronidazole for seven days, and were then randomised to one of five groups. For all five groups it was required that a vaginal tablet (either placebo or a variation of the LBP) was inserted intravaginally for seven days. The timing and composition of the LBP tablets varied slightly between the trial arms (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eBoth the VIBRANT study and qualitative sub-study were conducted in Boston, Massachusetts in the USA, and Vulindlela, KwaZulu-Natal in South Africa. Boston is a city of approximately 650,000 in a metropolitan area of over 4\u0026nbsp;million people, and is home to a large number of colleges and universities (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). The Boston study site was in a private hospital research clinic. Vulindlela is a rural area, consisting largely of \u003cem\u003eisiZulu\u003c/em\u003e speaking people, high levels of poverty, poor infrastructure and high HIV prevalence (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). Healthcare is accessible to community members through public health facilities located in this area. The Vulindlela study site was located in a research centre adjacent to a public health clinic.\u003c/p\u003e\u003cp\u003eThe VIBRANT study was conducted from February 2024 to February 2025 (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e) and the qualitative sub-study was conducted concurrently from February to December 2024. The overall aim of this qualitative study was to understand and explore the experiences and preferences of women using a vaginally delivered LBP in the clinical trial to inform future product development. One component was to specifically explore knowledge, impact and outcomes of a BV diagnosis, which is the focus of this manuscript.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eQualitative sub-study: Population and data collection\u003c/h3\u003e\n\u003cp\u003eQualitative sub-study participants were aged 18\u0026ndash;40 years, and were purposively selected from those participating in the VIBRANT study. We aimed to select a representative sample of approximately 15\u0026ndash;20 participants per study site (30\u0026ndash;40 in total), representing a range of participant ages and product use experience. All of these participants were invited to participate in a series of two in-depth interviews (IDIs) at two different timepoints in the clinical trial \u0026ndash; with the first IDI being conducted at, or soon after product use in the clinical trial, and the second IDI being conducted three weeks later, to determine if there had been any changes over time.\u003c/p\u003e\u003cp\u003eIn addition, we aimed to recruit about 5\u0026ndash;10 participants for once-off cases of interest IDIs. These could be done at any time point during the study, and included participants from the VIBRANT study who had note-worthy experiences during their participation in the clinical trial, including challenges with product insertion or adherence, early discontinuation of product, or those who were eligible to participate but chose not to participate.\u003c/p\u003e\u003cp\u003eThe IDIs had semi-structured interview guides developed specifically for this study (see supplementary files), and explored user experiences, product acceptability, facilitators and barriers to product adherence (and use) and the acceptability of an applicator for product insertion. The knowledge, emotional impact, and behavioural outcomes of a BV-related diagnosis and treatment were also explored. This latter thematic area is the focus of this manuscript.\u003c/p\u003e\u003cp\u003eAll IDI participants provided separate written or verbal consent to participate in the qualitative sub-study as per requirements of site-specific ethics boards. The IDIs were approximately 1-1.5 hours in duration, and were conducted in a quiet, private venue, at a time that was convenient to the participant. In Vulindlela, South Africa, interviews were conducted in person, and in Boston, USA, they were conducted over an online platform (such as Teams or Zoom) or in person depending on participant preference. Interviews were conducted by interviewers trained both in qualitative research and in sensitive research topics. In South Africa, all interviewers were female, bilingual (first language \u003cem\u003eisiZulu\u003c/em\u003e speakers), and all interviews were conducted in \u003cem\u003eisiZulu\u003c/em\u003e as preferred by the participants. In the USA, all interviews were conducted in English by a female researcher. The interviews were audio-recorded, with participants\u0026rsquo; consent.\u003c/p\u003e\u003cp\u003eDemographic and relevant quantitative behavioural data were collected as part of the VIBRANT study\u0026rsquo;s clinical component; for example, baseline behavioural sexual and reproductive health data, such as BV and sexually transmitted infections (STIs), were collected (see supplementary files for study specific baseline behavioural questionnaire).\u003c/p\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003eData analysis\u003c/h2\u003e\u003cp\u003eRelevant clinical trial demographic and baseline behavioural data were descriptively analysed using medians, interquartile ranges (IQR), percentages and frequencies in SAS, version 9.4 (SAS Institute Inc). These data were used to describe participants\u0026rsquo; sociodemographic characteristics and individual-level BV and STI history.\u003c/p\u003e\u003cp\u003eIDIs were transcribed and translated into English (where necessary). Once transcribed, the study team (CM, TSH, BLD, MNM) developed a single code list, based on a review of a representative set of transcripts from both study sites. The code list was informed both by thematic areas arising from the data, as well as through the structure of the IDI guide, which influenced the topics of discussion. This code list was reviewed by a USA team member (NAM) to ensure that it was representative of USA study data. The initial code list was tested on additional transcripts (by CM, TSH, BLD and MNM), and any differences and similarities in interpretation were discussed and the code list was revised. Once agreement was reached, transcripts and the code list were imported into qualitative data analysis software, NVivo version 15 (QSR International), and all transcripts were double coded. Team members met regularly to discuss and compare coding, and to ensure that inter-coder agreements were met throughout the coding process. Once all data were coded, coding reports were generated to create summaries of key codes, and data were organised for a thematic analysis. Thematic areas are described in the results section below.\u003c/p\u003e\u003cp\u003eData triangulation was used to compare findings from the VIBRANT study baseline behavioural questionnaire with IDI findings.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eEthical considerations\u003c/h3\u003e\n\u003cp\u003e This qualitative sub-study was approved by the Biomedical Research Ethics Committee (BREC) of the University of KwaZulu Natal (BREC/00006221/2023) and the Mass General Brigham (MGB) Institutional Review Board (IRB) (2023P003545). All participants provided written or verbal informed consent to participate in the IDI, with separate consent for audio recording of their IDIs. Consenting was conducted in \u003cem\u003eIsiZulu\u003c/em\u003e or English, depending on participant preference.\u003c/p\u003e\u003cp\u003eThe VIBRANT study received separate ethics approval from BREC (Reference: BREC/5620/2023) and the MGB IRB (2023P001035).\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eNinety-six participants were randomised and enrolled in the VIBRANT study (24 at Boston, USA and 72 at Vulindlela, South Africa).\u003c/p\u003e\u003cp\u003eAt the Vulindlela site, 20 clinical trial participants participated in two serial IDIs, and 3 completed once-off, cases of interest, IDIs. These cases of interest included one participant who did not use her first study product, one participant who shared her study product with her sister, and one who had challenges with study product insertion. There were no refusals to participate in the serial IDIs in South Africa, but there were 2 participants who refused or were unavailable to participate in cases of interest IDIs.\u003c/p\u003e\u003cp\u003eAt the Boston site, 12 clinical trial participants completed the first serial IDI and, of these, 10 completed the second serial IDI. One participant did not return for her second IDI, and another was interviewed late for her first IDI, so did not complete a second IDI due to being out of window. The enrolment rate in the VIBRANT study was slow at this site, resulting in a smaller number of enrolled participants. Therefore, recruitment for the IDIs was impacted and, due to a smaller pool of clinical trial participants, a decision was made to reduce the target serial IDI enrolment to at least 10 participants. There were 2 once-off, cases of interest IDIs at this site \u0026ndash; one product discontinuer, and one participant who had enrolled but chose not to use the study product. Similarly, due to the smaller number of enrolled VIBRANT study participants, no additional cases of interest were identified. There were no refusals to participate in any IDIs.\u003c/p\u003e\u003cp\u003eThe median age of IDI participants was 28 years (26 years at Vulindlela, and 31 years at Boston). Of these IDI participants, 38% (n\u0026thinsp;=\u0026thinsp;14) reported that they had previously been diagnosed with BV and had received BV treatment a median (IQR) of 3 (\u003cspan additionalcitationids=\"CR2 CR3 CR4 CR5 CR6 CR7 CR8\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e) times in the past year (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The most commonly reported antibiotics used for treatment of past BV and/or vaginal symptoms were metronidazole, clindamycin and azithromycin, but 46% (n\u0026thinsp;=\u0026thinsp;17) reported no antibiotic use. Use of other treatments, most commonly vaginal cream, oral probiotics and boric acid, was also reported. Compared to the site in Boston, the site in Vulindlela had lower prevalence of BV diagnosis (86% versus 9%), antibiotic use (79% versus 22%) and other product use (71% versus 26%). Overall, 19% (n\u0026thinsp;=\u0026thinsp;7) reported having a previous STI diagnosis.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eBV and STI history and treatment\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eVulindlela (N\u0026thinsp;=\u0026thinsp;23)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eBoston (N\u0026thinsp;=\u0026thinsp;14)\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePreviously diagnosed with BV, % (n)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e8.7(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e85.7(\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNumber of times treated in the past year for BV (among those previously diagnosed with BV), median (IQR)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3(2-9.5)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNumber of times treated for vaginal symptoms in the past year (among those not previously diagnosed with BV), median (IQR)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0\u0026ndash;1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.5(0\u0026ndash;1)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePrevious treatment for vaginal symptoms/ BV\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAntibiotics used, % (n)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMetronidazole\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e17.4(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e71.4(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eClindamycin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e28.6(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTinidazole\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAzithromycin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e13(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDoxycycline\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4.3(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14.3(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAntibiotic injection\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e13(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDo not know\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e17.4(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo antibiotic used\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e60.9(\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e21.4(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eOther treatments used, % (n)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eVaginal cream\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e21.7(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e50(\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHome remedies\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4.3(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eOral probiotics\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e28.6(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eVaginal probiotics\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4.3(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBoric acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e35.7(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eOther treatment\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNo other treatment\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e73.9(\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e28.6(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eHistory of STIs (ever diagnosed), % (n)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGonorrhoea\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4.3(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14.3(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eChlamydia\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e35.7(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTrichomonas\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHerpes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHPV\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0(0)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNone of the above\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e52.2(\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e50(\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDon\u0026rsquo;t know if I had STI\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e43.5(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.1(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e[Insert Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e]\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eThematic results\u003c/h2\u003e\u003cp\u003eStudy findings have been thematically organised according to five key themes: 1) prior BV and other vaginal health related experiences; 2) previous vaginal health seeking behaviour/treatments used; 3) BV knowledge, attitudes, and reactions to BV diagnosis; 4) behavioural changes because of BV experiences; 5) vaginal health/hygiene practices because of BV experiences; and 5) BV diagnosis disclosure patterns. Any differences and similarities between sites are highlighted.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003ePrior BV and other vaginal health experiences\u003c/h3\u003e\n\u003cp\u003eDuring the IDIs, none of the participants at the Vulindlela site specifically reported that they had previously been diagnosed with BV (although two did report previous diagnoses during their clinical trial baseline behavioural assessment). However, almost all Vulindlela IDI participants described previous vaginal health concerns \u0026ndash; the majority reporting having had experienced a smelly discharge, itchiness or pain during urination, some of which had been diagnosed and treated as STIs.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eThe problem is that itches deep inside where I can't scratch and where I am unable to touch, and if I ever move the flesh, I swell up. (Vulindlela, 36 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI had something that was coming out, that was some kind of discharge. It was different, it would be brown, and sometimes it would be yellowish, and sometimes it would be white and clean. (Vulindlela, 34 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eIt is that my vagina would times have a bad odour. Water [fluid from the vagina] would come out that smells. (Vulindlela, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eConversely, most IDI participants from Boston reported a previous BV diagnosis. Those who didn\u0026rsquo;t, made reference to having had BV-related symptoms in the past. Almost all of these participants had experienced multiple recurrences of BV infection, after various treatment options, and were desperate to treat their BV symptoms.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI had the BV, and ever since July, I swear to God, it's been BV, yeast, BV, yeast, BV, yeast\u0026mdash;back to back to back to back. I've racked up so much money going to my gynaecologist, just with the appointment fees, because they're a specialist\u0026mdash;and it really sucks. (Boston, 26 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eAfter they did the treatment, they did another test, and the test showed that everything is good. Your vagina is happy, but like a month later, the symptoms came back, did another test, and it says, \u0026ldquo;Yes, your vagina is now mad.\u0026rdquo; The tests match with my experience, but the treatment, I wouldn't say it didn't help, but it doesn't stay. (Boston, 40 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eIn addition, participants from Boston also reported having experienced other vaginal/sexual and reproductive health (SRH) concerns. The majority reported experiencing yeast infections or urinary tract infections (UTI). Endometriosis, polyps in the uterus, and an ovarian cyst were also listed as previous sexual health concerns.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI would be prone to yeast infections or UTIs growing up, but I never was officially diagnosed with BV until actually having an IUD [intra-uterine device]. (Boston, 24 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI've had a polyp, [\u0026hellip;] recently in the uterus, taken out, and I've had\u0026ndash;\u0026ndash;what do you call it? [\u0026hellip;] A cyst. I've had a cyst in the ovaries before. (Boston, 38 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\n\u003ch3\u003ePrevious health seeking behaviour and treatments used\u003c/h3\u003e\n\u003cp\u003e Almost all participants from both Boston and Vulindlela had sought treatment for previous vaginal health concerns. Many of them described recurrence of symptoms, and repeated treatments required.\u003c/p\u003e\u003cp\u003e The majority of participants at Vulindlela had been to the local clinic or a doctor for treatment of vaginal discharge, malodour or itchiness, and had been treated with oral tablets and/or an injection. A few had been provided with vaginal cream to insert and/or apply, and only two described being given a vaginal tablet to insert. Participants did not provide details of the names of the treatment they had used.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eIt would come back at a later stage, this discharge. [\u0026hellip;.] I would go to the clinic and be given some\u0026hellip;some pills. They would give me pills and something else...Ya, last time, I last went last year, even though I don't remember when it was, but they gave me pills and injected me. [\u0026hellip;.] I was drinking them, it was drinkable pills. [\u003cb\u003eI\u003c/b\u003e\u003c/strong\u003e\u003cp\u003e\u003cb\u003eOh, the cream?]\u003c/b\u003e \u003cem\u003eNo, they have never given me. [\u0026hellip;] It was drinkable pills then an injection. (Vulindlela, 36 years)\u003c/em\u003e\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI\u0026rsquo;ve went to the clinic before, they injected me and said I have STIs. I got an injection [\u0026hellip;]. Only, after that the infection came back again. (Vulindlela, 36 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e[W]hen I had a discomfort, and it was severe. It made me go and see the doctor. [\u0026hellip;.] Because she gave me a\u0026hellip;was it a cream? A vaginal cream, that I inserted at night. It was cream only. (Vulindlela, 34 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eThere was\u0026hellip;there was\u0026hellip; [a tablet that you had to insert in your vagina] [\u0026hellip;.] It is shaped exactly like the tablet that from here [research site] and its colour. [\u0026hellip;.] They [local clinic staff] gave me the one that you insert. [\u0026hellip;.] It treated me well because I got the help. [\u0026hellip;.] It helped me because what I had got treated, I didn\u0026rsquo;t have it anymore. (Vulindlela, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eSome participants from Vulindlela described challenges accessing treatment/care from local clinics, largely due to staff attitudes, and preferred to access treatment elsewhere, for example private pharmacies.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eIt\u0026rsquo;s just that some nurses have tendencies that are not alright. When you come to a nurse because you have a problem, but they will call another one, you see now? \u0026ldquo;Tell us again, what is wrong with your vagina?\u0026rdquo; You see, now you are getting embarrassed, [\u0026hellip;.] You leave the clinic not feeling alright. So, the pharmacy is better. The pharmacy doesn\u0026rsquo;t ask anything. You get there, you say the problem that you are facing, they get you what will help you and you leave. (Vulindlela, 25 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eMost participants from Boston reported previously being prescribed with antibiotics, such as metronidazole, for their BV symptoms. Some reported taking oral antibiotics, others reported using a cream, or suppositories for treatment. Many of them also described using boric acid to relieve their symptoms. Treatment success was reportedly not high, with many participants reporting using multiple treatment options for recurrent symptoms.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI have been trying too many options. The doctor, she just send[s] more antibiotics, more antibiotics, more, more, and then nothing is being helpful. [\u0026hellip;.] I have been using the boric acid [\u0026hellip;.] That was working. [\u0026hellip;.] At least feel better. Yeah, the discharge minimized, and that was helpful. (Boston, 38 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI feel like in the past when I've used the metronidazole cream, I had very minimal relief, and same with the [vaginal] tablet too. Maybe I've grown a tolerance to both, I don't know, but I feel like the tablet\u0026mdash; it was definitely more effective than both. Upon my initial diagnosis, I was prescribed metronidazole tablets, and with that, my symptoms did not change at all. (Boston, 24 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI did try the boric acid. I've never heard of it until I did a little research, and it said it can help with some symptoms. I tried that maybe earlier this year. I couldn't tell if it helped, really, \u0026lsquo;cause I had some itching at the time and so I tried that. It was okay, but I don't think it was a long-term method which they advertised. It just helps relieve symptoms. I've tried that. Nothing else other than that. (Boston, 29 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e The majority of participants from Boston reported being prescribed medication by their doctors, gynaecologists or primary care physicians.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eEverything that I know about my vagina is questions I've asked my gynecologist, and I just trust whatever\u0026mdash;whatever she says, I trust. (Boston, 26 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003eSelf-care practices\u003c/h2\u003e\u003cp\u003eThere were also various reports of self-care/self-help practices used by participants from Vulindlela and Boston to treat or alleviate their symptoms. Some Vulindlela participants described steaming or hygiene practices.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003ePeople just know that if you have a problem there [vagina], you steam using water and onion, done! (Vulindlela, 25 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e[T]here is nothing I did, I would just take water, pour it in the basin and bath to make it [her vagina] cooler because it was painful and inflamed, and when I have washed it with water the pain would decrease, but there is no pill that I can say helped me, no there isn\u0026rsquo;t. (Vulindlela, 36 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e A couple of participants from Vulindlela reported using citro soda/potassium citrate to alleviate their vaginal malodour, and there were reports of searching online or via social media for remedies.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI used to buy citro soda [\u0026hellip;] I used to drink that thing. [\u0026hellip;] I learned on TikTok [social media platform name] that it resolves smelly odour, which is what I had, so I used to drink it and it would help me for like two days and will have to do it again and again. (Vulindlela, 20 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI talk to my friend, the two of us because when she has a problem, she asks me and says, \u0026ldquo;you know, I am going through such and such\u0026rdquo;. We usually sit down, and search on google on what could help us. (Vulindlela, 27 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eA few participants from Boston few described scepticism of the healthcare system, which lead to self-help treatment. Some bought over-the-counter treatment, with some reporting using probiotics and one reporting using cannabidiol (CBD) suppositories for BV treatment. In Boston, one participant mentioned that some people would use yoghurt, steam or douche their vaginas as an alternative to accessing the health system.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI think people have fraught relationships with the medical system and I think that is part of the reason why, or yeah, I think that's part of the reason why many women have turned to these alternative products that might be harmful, but they're desperate for anything and they don't feel like they can get the help they can within the medical system, unfortunately. People who put yogurt in their vaginas or use steam douching or things like that. (Boston, 25 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eIn the past, I've also used CBD repositories. Especially while I was on my period. I heard that that would relax my muscles somehow. I've tried that. (Boston, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\u003ch2\u003eBV knowledge, attitudes and reactions to BV diagnosis\u003c/h2\u003e\u003cp\u003eNo participants from Vulindlela described any knowledge about BV prior to joining the VIBRANT study. Once they joined, they learnt about it and demonstrated varying degrees of understanding of BV. All participants from Boston demonstrated that they understood/had some knowledge about BV.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI know that BV is found in almost 25% of the women worldwide. You can see it when you have a white discharge that has a bad odour. It happens sometimes that the vagina might be itchy or have pimples or experience inflammation. [\u0026hellip;] I didn\u0026rsquo;t know all that knowledge [before joining the study]. I got it when I was in the study here. (Vulindlela, 19 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e Participants were asked to describe how finding out about their BV status impacted them in their daily lives. This was closely related to their attitudes to BV. The majority of participants from Vulindlela had not previously been diagnosed with BV, and were first diagnosed during participation in the VIBRANT study. Of these, the majority first expressed fear, shock or surprise about their diagnosis. However, this was soon replaced with relief that the BV could be treated during the study.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eIt scared me, I don\u0026rsquo;t want to lie. I got scared, and I was very shocked that [\u0026hellip;] I didn\u0026rsquo;t think that something like this could be found on me. [\u0026hellip;] I thought that it was a bad thing, yho! I thought it was just a bad thing, shame, and maybe something big, maybe that cannot be cured. [\u0026hellip;] I learnt about it and they said that it is curable. (Vulindlela, 25 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eA couple of Vulindlela participants had previously suspected that they had a vaginal health issue, and were happy to be diagnosed. Others had no concerns with their diagnosis, although were happy to know about their health status.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003e[W]hen I got here and it [BV] was explained do me, by knowing myself as a woman, I had already seen that there is an infection that I have. (Vulindlela, 34 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e In contrast, the majority of participants from Boston were aware of their BV status before joining the study. They described how the knowledge of having BV was not as impactful as actually experiencing BV. For them, BV was viewed as negative \u0026ndash; described as irritating and uncomfortable, impacting daily life, including sex, intimacy and social situations.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI'm happy that I can just say, \"Oh, yeah, I have BV,\" and get medication for it. It's 97 cents. It's not expensive. Knowing that I have BV is a non-issue. It's the BV itself which is the issue. [\u0026hellip;.] I can't have sex easily. When I do have sex, it hurts. Not to mention that just walking around all day\u0026mdash;I have all this constant discharge. It's painful, it's burning. It dries up my everything down there, and it smells like hell. The thing is, I take a shower every day. I'm a clean person. I changed my underwear. I've always been a clean person. Now that I have this recurring BV, it makes me feel dirty, because nothing that I do works, and it always smells bad. I can't have sex, and I hate that. I can have sex, but it hurts like hell. (Boston, 26 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e[A]s a woman, \u0026rsquo;cause it [BV] makes you feel weird. I guess it's something you can smell, but nobody else can smell, but you think everybody else can smell it. The fishy odour is nasty. [\u0026hellip;] Especially being a female. You'll be sitting around a group of people, and you're like, \u0026ldquo;I smell myself. I'm pretty sure everyone else smells it\u0026rdquo;. (Boston, 38 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e Some Boston participants described that they felt better knowing that there were other people who also had BV and that they were not alone. This had positive implications for their wellbeing.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eMy views [on BV] haven\u0026rsquo;t changed. What I have learned is, again, I\u0026rsquo;m not the only one, so don\u0026rsquo;t feel ashamed or embarrassed. (Boston, 34 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003eBehavioural changes because of BV experiences\u003c/h2\u003e\u003cdiv id=\"Sec14\" class=\"Section3\"\u003e\u003ch2\u003eVaginal health and hygiene practices\u003c/h2\u003e\u003cp\u003e Some participants at both sites described their vaginal cleaning practices, especially to address their BV symptoms. Some participants from Boston and Vulindlela made use of feminine washes and/or wipes to address malodour and discharge that were experienced from BV.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eSo, when we talk, they [friends] usually ask me, \u0026ldquo;hey, what makes you not to have a smell?\u0026rdquo; Then I told them that, \u0026ldquo;as much as I use GynaGuard [intimate wash soap] when I bath\u0026rdquo;. I told them they must use it. (Vulindlela, 27 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI\u0026rsquo;ll use feminine washes. Feminine washes, detox pearls, boric acid. That\u0026rsquo;s as far as it goes. (Boston, 28 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e Other participants described avoiding use of soap or using gentle soap to clean their vaginas.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003e\u0026ldquo;Ay me, I bath with water\u0026rdquo;. I just bath, then I use cold water to wash my vagina. (Vulindlela, 20 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI try to avoid getting soap anywhere near the inside. I try to keep it as far from the outside as I can, or on the outside. (Boston, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eFrequency of washing varied between individuals, from 1 to 3 or 4 times per day.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI usually washed in the morning, and I would wash again when I was going to bed. (Vulindlela, 27 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI shower in the morning, and I shower after the gym, and then sometimes I shower at night, depending if I go out. (Boston, 40 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e A few Vulindlela participants reported changes in their hygiene practices after their BV diagnosis during the study.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003e[B]efore I came, when I had the, the discharge that was coming out with a smell, I ended up trying to buy wipes, you see? [\u0026hellip;] But when I got here [research centre], we were told, \u0026ldquo;For now, can you stop using soap\u0026rdquo;. I would then just bath my body then take something to get water and clean it with cold water. (Vulindlela, 34 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eThey taught me that as I still have BV, [\u0026hellip;.] when I was cleaning the private part, I must not insert a finger, because the finger has germs. (Vulindlela, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e Similar to Vulindlela, some Boston participants changed their vaginal hygiene practices during the study, including showering/cleaning more regularly.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eAs far as instead of two showers a day, it would be three showers a day type thing. (Boston, 33 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003eChanging clothes/laundry practices\u003c/h2\u003e\u003cp\u003e In addition, Boston participants reported that they had to change their underwear more regularly or do laundry more often because of the associated discharge and odour of BV.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eIt comes with strong odour, discharge. Uncomfortable, I have to change my underwear twice to three times a day sometimes. (Boston, 32 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI get wet because the discharge is mostly liquid. It's mostly uncomfortable. I need to change my panties and my panty liners frequently. Sometimes, I don't know this is me, but I can smell it. All of that. (Boston, 38 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003eChanges to sexual behaviour/practices\u003c/h2\u003e\u003cp\u003eChanges to sexual practices as a result of BV diagnosis were not discussed at Vulindlela. This is possibly because participants were first diagnosed with BV during the study, therefore there was no previous real life experience to draw on. However, one participant reported that because of her BV, she was advised to use a condom during sex.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eThey taught me that as I still have BV, I have to use a condom when I have sex. (Vulindlela, 24 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eParticipants from Boston reported more changes in sexual behaviour as a result of BV \u0026ndash; some reported abstaining, and others reported reducing the amount of sex or changing sex acts (e.g. no more oral sex). These changes were made because of being self-conscious about the BV related malodour, because of discomfort during sex, and their perceived impact of sex on the recurrence of BV symptoms.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eYeah, the symptoms are very\u0026ndash;\u0026ndash;it affects your life a lot. I'm not gonna have sex with someone when it smells bad. Yeah, it makes me very uncomfortable, very self-conscious. Yeah, it made me feel kind of gross. (Boston, 40 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e Oral [sex] had already been impossible 'cause I'd been having recurrent BV, and that recurrent like smell and discharge. (Boston, 26 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\u003ch2\u003eBV diagnosis disclosure patterns\u003c/h2\u003e\u003cp\u003e Only some participants from Vulindlela and Boston disclosed their BV status to others. Participants from Vulindlela were more likely to disclose to female family members (mothers, sisters, grandmothers and/or aunts), whereas participants from Boston were more likely to disclose to their partners. Although, there were a few participants from Vulindlela who did disclose their BV diagnosis to their partners, and a few from Boston who did tell female family members about their BV. The level of detail disclosed also varied between participants.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI just thought, okay, I will tell my mother, even though I will not tell her every single thing, but I will tell her that there is this kind of a pill, and they say that it treats the BV disease. Even though I will not tell her deeply about what it is. (Vulindlela, 19 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003e[S]o my partner's actually in medical school [laughs], so actually it's helpful. I think with my partner, I'm pretty much completely transparent about all aspects of it [BV]. With my mom, I think I was\u0026mdash;maybe I didn't need to be this honest, but I basically told her the reason, I was like, \"I think this happened is because I had sex without a condom.\" She was like, \"Oh my god.\" (Boston, 25 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eA few participants also disclosed to friends. Some participants reportedly disclosed their BV status for altruistic reasons, as they wanted others to get information and help for BV if necessary.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI used to tell others too because some people don\u0026rsquo;t know about the illness called BV, which comes out of a person\u0026rsquo;s private part, of a woman. (Vulindlela, 20 years)\u003c/em\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eI feel like dealing with this condition since the end of last year has very clearly impacted my life, and so I feel like if I'm catching up with a friend and they're like, \"How are you doing?\" I'm like, \"Well, I've been dealing with some health stuff.\" Then very naturally, they're like, \"Oh, what kind of health stuff [laughs]?\" I'm like, \"Okay, well there's this thing called BV.\" I think in general, yeah, I've just been\u0026mdash;I've tried to be open about it because I think part of the reason why conditions like this aren't studied is because people are hush hush about it because it is extremely embarrassing and stigmatizing, but I think openness is probably better than not openness. (Boston, 25 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eParticipants had varying reasons for disclosing to some and not to other people, as described by one Vulindlela participant:\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eIt was only my Mother, it was my Mother and my sister who knew. [\u0026hellip;.] I didn\u0026rsquo;t tell my partner. \u003cb\u003e[I\u003c/b\u003e\u003c/strong\u003e\u003cp\u003e\u003cb\u003e[F]riends, have you ever told your friends?]\u003c/b\u003e \u003cem\u003e[\u0026hellip;.] Oh, what made me to tell my friends is because, isn\u0026rsquo;t it we are all on family planning, so I thought maybe they could also be able to come here [to the research centre] \u0026hellip; to get this research that is about BV. Maybe they can also get helped as I also got helped. What made me not to tell my partner is because he was going to judge me. He likes to be judgemental. (Vulindlela, 25 years)\u003c/em\u003e\u003c/p\u003e\u003c/p\u003e\u003cp\u003eSome people did not disclose their BV status at all:\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e\u003cem\u003eI don't share with people. Not too much because it's a study product, but because it's bacterial vaginosis. No one wants to talk about that. If it was a study product for any other\u0026mdash;if it was for throat pain, I would happily share it with the world, but no[one] needs to know I have BV. (Boston, 40 years)\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eSimilar to previous research, women in this study had poor levels of awareness of or knowledge about BV prior to being diagnosed with it (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). In this study, few South African participants had previously been diagnosed with BV, compared with the USA participants, who had mostly had a previous BV diagnosis. As a result, most USA participants demonstrated a good knowledge of BV, whereas South African participants had limited knowledge or awareness before their participation in the VIBRANT study. However, participants from both countries reported similar past SRH and vaginal health experiences \u0026ndash; including increased vaginal discharge and malodour, typical of BV (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e), as well as recurrence of these symptoms after treatment.\u003c/p\u003e\u003cp\u003eIn South Africa, the standard treatment guidelines for primary health care, recommend that STIs are syndromically managed in order to be able to treat more than one condition that could be occurring at the same time (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). Furthermore, this is exacerbated by limited resources in some health care settings. However, this practice of treating symptoms rather than testing for STIs or BV specially, could be the reason for limited previous diagnosis in South African participants.\u003c/p\u003e\u003cp\u003eParticipants in this qualitative study described various treatment strategies and drug formulations accessed for their vaginal health conditions or BV symptoms, prior to their participation in the VIBRANT study (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). These included oral tablets, injections, vaginal creams, and vaginal inserts/tablets. Specifically, antibiotics such as metronidazole, were reported by USA participants as recommended for BV treatment (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). However, attitudes of healthcare workers and reduced faith in treatment because of recurrence of symptoms resulted in participants reporting trying self-care treatment strategies. This move to alternative, self-help treatment strategies including using boric acid, douching, probiotics and yoghurt has also been reported elsewhere (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). In South Africa, where there is a strong reliance on traditional healing in some cultures, it is surprising that participants did not describe accessing these services. However, there were reports of vaginal steaming and douching by a few South African participants.\u003c/p\u003e\u003cp\u003eIn this study, participants who reported previous BV diagnosis described how their BV symptoms, malodour and vaginal discharge, as well as the concern that sex could trigger BV, had impacted their sexual behaviours \u0026ndash; including abstinence and reducing frequency of sex. Previous research describes that decreased sexual quality of life can also result in depression, distress and relationship disruptions (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). Furthermore, participants in this study demonstrated shame and embarrassment as a result of BV symptoms. These negative psychosocial impacts of BV can result in reducing quality of life (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). However, participants in this study revealed that knowing that others suffered from BV made them feel less ashamed, which had positive implications for their wellbeing.\u003c/p\u003e\u003cp\u003e Experiences of BV also resulted in participants reporting changes in their vaginal hygiene and/or washing practices, both to decrease symptoms as well as to reduce potential for BV recurrence. Initially, participants described more frequent washing, and the use of feminine washes or wipes to address malodour and discharge. However, as highlighted elsewhere, soaps used to wash the vagina have been viewed as triggers for BV (\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e), and use of soap free washes have been reported for vaginal hygiene (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). Similarly, some participants in this study described avoiding soap or using gentle soaps to clean their vaginas after BV diagnosis. In addition, USA participants in this study described frequently changing their underwear, or more frequently washing their clothes because of the increased vaginal discharge and malodour of BV. Women in other research also report changing their underwear more frequently (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e), or choosing clothing accordingly \u0026ndash; choosing cotton underwear, avoiding tight clothing, and wearing clothing that encourages ventilation to manage their BV symptoms (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e South African participants were more likely to disclose their BV diagnosis to female family members and USA participants were more likely to disclose to their male sexual partners. South African participants often lived with other female family members, and this could have impacted on their decisions to tell them. Although USA participants did not always live with their male partners, many were in committed relationships. Other studies have demonstrated that disclosure to certain people is often related to the need for encouragement and support (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). Some participants at both sites disclosed to their friends, and this was often altruistic in nature \u0026ndash; where they wanted to provide information and guidance to others who may also experience BV. Previous research found that single women were less likely to discuss their BV diagnosis with casual partners and more likely to discuss it with friends, whereas women in relationships were more likely to discuss their concerns with regular partners, but also commonly discussed their diagnosis with friends as a means of information gathering (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). By disclosing to partners, women have been able to get support with managing symptoms in intimate exchange/sexual encounters (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e\u003ch2\u003eFuture recommendations\u003c/h2\u003e\u003cp\u003eThis research highlights the lack of adequate diagnosis and treatment of BV in the healthcare setting, especially in the South African population. There is a need for healthcare staff to learn to differentiate BV from other conditions, and to treat it appropriately (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). Healthcare provider training on BV identification and management in resource constrained settings, where syndromic management of STIs is recommended (\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e) could facilitate further identification and appropriate management of BV. Further studies are required to be able to identify strategies to treat BV so that there is minimal recurrence (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eHealthcare providers have an obligation to provide clients with better BV related information, knowledge and support (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). The benefits of medical versus self-care treatment strategies need to be understood, and awareness and education should also target this. Education and support need to extend beyond the healthcare setting, creating increased awareness of BV, with targeted advertising campaigns and education in schools and communities around SRH and BV (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). With improved public knowledge, stigma and psychosocial impacts of BV can be better managed and supported.\u003c/p\u003e\u003cp\u003eIn order to assess the burden of BV, more quantitative studies can be conducted to explore the impact of/association of BV with emotional, sexual and social health (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). Through this, targeted support can be provided to people who are diagnosed with BV. Appropriate diagnosis and treatment and support are critical to ensure that BV is adequately managed and that quality of life and associated stigma and health risks of BV are eliminated.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec20\" class=\"Section2\"\u003e\u003ch2\u003eLimitations\u003c/h2\u003e\u003cp\u003eAs with any study, there are some limitations. Due to the qualitative nature of the study, the findings are limited in generalisability, but are exploratory in nature. Although there are some differences between the USA and South African participants\u0026rsquo; reports, these may be specific to the regions in which the study was conducted. However, there are some findings which are more general, and which highlight some of the important challenges with BV knowledge and treatment experiences, which are useful for future research and education on BV.\u003c/p\u003e\u003c/div\u003e"},{"header":"Conclusions","content":"\u003cp\u003eBV knowledge, attitudes and experiences are related to previous diagnosis and treatment. However, experiences of symptoms impact individuals\u0026rsquo; behaviours, regardless of previous diagnosis. Experiences of discharge, malodour and discomfort all have psychosocial impacts which cannot be appropriately addressed without access to appropriate counselling and treatment options. There is a need to ensure that there is ongoing research for effective BV prevention and treatment options that can be made available and accessible to women with BV globally.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eBREC:\u0026nbsp; \u0026nbsp;\u0026nbsp;Biomedical Research Ethics Committee\u003c/p\u003e\n\u003cp\u003eBV:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Bacterial vaginosis\u003c/p\u003e\n\u003cp\u003eCBD: \u0026nbsp; \u0026nbsp; \u0026nbsp;Cannabidiol\u003c/p\u003e\n\u003cp\u003eHIV:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Human immunodeficiency virus\u003c/p\u003e\n\u003cp\u003eIDI:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;In-depth interview\u003c/p\u003e\n\u003cp\u003eIQR:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Interquartile range\u003c/p\u003e\n\u003cp\u003eIRB:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Institutional Review Board\u003c/p\u003e\n\u003cp\u003eIUD:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Intra-uterine device\u003c/p\u003e\n\u003cp\u003eLBP:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Live biotherapeutic product\u003c/p\u003e\n\u003cp\u003eMGB:\u0026nbsp; \u0026nbsp;\u0026nbsp;Mass General Brigham\u003c/p\u003e\n\u003cp\u003eSRH:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Sexual and reproductive health\u003c/p\u003e\n\u003cp\u003eSTI:\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Sexually transmitted infection\u003c/p\u003e\n\u003cp\u003eUSA:\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;United States of America\u003c/p\u003e\n\u003cp\u003eUTI: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Urinary tract infection\u003c/p\u003e\n\u003cp\u003eVIBRANT:\u0026nbsp;Vaginal lIve Biotherapeutic RANdomized Trial\u003c/p\u003e"},{"header":"Declarations","content":"\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eFunding: \u003c/strong\u003eThis work was funded by the Gates Foundation under under INV-037901 and INV-037902.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eConflict of interest: \u003c/strong\u003eThe authors CM, BLD, NAM, TSH, LL, AAK, MNM and DP declare that they have no conflict of interest. Dr. Mitchell has served as a consultant for Freya Biosciences, Concerto Biosciences and Ancilia Biosciences. Dr. Mitchell has a financial interest in Ancilia Biosciences, a company developing a new class of Live Biotherapeutics and other bacterial products. Dr. Mitchell\u0026rsquo;s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eEthics approval:\u003c/strong\u003e Ethics approval was obtained from the Biomedical Research Ethics Committee (BREC) of the University of KwaZulu Natal (BREC/00006221/2023) and the Mass General Brigham (MGB) Institutional Review Board (IRB) (2023P003545). \u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eConsent to participate:\u003c/strong\u003e All participants provided written or verbal informed consent to participate in the IDI, with separate consent for audio recording of their IDIs. \u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eConsent for publication: \u003c/strong\u003eNot applicable, individual data/images not used.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eAvailability of data and material: \u003c/strong\u003eAccess to the data from this sub-study may be requested through submission of a research concept to the corresponding author at [email protected]. The concept must include the research question, data requested, analytic methods, and steps taken to ensure ethical use of the data. Access will be granted if the concept is evaluated to have scientific merit and if sufficient data protections are in place. \u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eAuthors contributions: \u003c/strong\u003eCM, CMM and DP contributed to the study conception and design. Data collection was conducted by BLD, MNM, NAM and AK. Qualitative data analysis was performed by CM, BLD, MNM and TSH. Quantitative data analysis was conducted by LL. The first draft of the manuscript was written by CM. All authors provided input to the draft, and read and approved the final manuscript. \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements: \u003c/strong\u003eThis study was funded by the Gates Foundation (INV-037901 and INV-037902). The authors would like to thank the participants for their time for participating in this study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAbou Chacra L, Fenollar F, Diop K. Bacterial Vaginosis: What Do We Currently Know? Frontiers in Cellular and Infection Microbiology. 2022;11:672429.\u003c/li\u003e\n\u003cli\u003eWoodman Z. Can one size fit all? Approach to bacterial vaginosis in sub-Saharan Africa. Annals of Clinical Microbiology and Antimicrobials. 2016;15:16.\u003c/li\u003e\n\u003cli\u003eBilardi J, Walker S, McNair R, Mooney-Somers J, Temple-Smith M, Bellhouse C, et al. Women\u0026apos;s Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. PLoS One. 2016;11(3):e0151794.\u003c/li\u003e\n\u003cli\u003eChow K, Wooten D, Annepally S, Burke L, Edi R, Morris SR. Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments. BMC Womens Health. 2023;23(1):112.\u003c/li\u003e\n\u003cli\u003ePeebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sexually Transmitted Diseases. 2019;46(5):304\u0026ndash;11.\u003c/li\u003e\n\u003cli\u003eNyemba DC, Haddison EC, Wang C, Johnson LF, Myer L, Davey DJ. Prevalence of curable STIs and bacterial vaginosis during pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. Sexually Transmitted Infections. 2022;98(7):484\u0026ndash;91.\u003c/li\u003e\n\u003cli\u003eTorrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(2):e1002511.\u003c/li\u003e\n\u003cli\u003eBilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women\u0026apos;s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013;8(9):e74378.\u003c/li\u003e\n\u003cli\u003eBrusselmans J. The emotional, sexual and social impact of (recurrent) Bacterial Vaginosis: A systematic review: University of Ghent; 2020.\u003c/li\u003e\n\u003cli\u003eBrusselmans J, De Sutter A, Devleesschauwer B, Verstraelen H, Cools P. Scoping review of the association between bacterial vaginosis and emotional, sexual and social health. BMC Womens Health. 2023;23(1):168.\u003c/li\u003e\n\u003cli\u003eAdolfsson A, Hagander A, Mahjoubipour F, Larsson P-G. How Vaginal Infections Impact Women\u0026rsquo;s Everyday Life \u0026amp;lt;br/\u0026amp;gt;\u0026mdash;Women\u0026rsquo;s Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis. Advances in Sexual Medicine. 2017;07(01):1\u0026ndash;19.\u003c/li\u003e\n\u003cli\u003eBilardi J, Walker S, Mooney-Somers J, Temple-Smith M, McNair R, Bellhouse C, et al. Women\u0026apos;s Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated with Recurrence. PLoS One. 2016;11(3):e0150272.\u003c/li\u003e\n\u003cli\u003eCDC. Sexually transmitted infections treatment guidelines, 2021. 2021. https://www.cdc.gov/std/treatment-guidelines/default.htm. Accessed 01 Sep 2025.\u003c/li\u003e\n\u003cli\u003eWorkowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. Morbidity and Mortality Weekly Report, Recomm Rep. 2021;70(No. RR-4):1\u0026ndash;187.\u003c/li\u003e\n\u003cli\u003eNational Department of Health (NDoH), Essential Drugs Programme. Primary Healthcare Standard Treatment Guideline and Essential Medicine List. South Africa; 2024. https://www.health.gov.za/nhi-edp-stgs-eml/. Accessed 25 Aug 2025.\u003c/li\u003e\n\u003cli\u003eBradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with Recurrence. Journal of Infectious Diseases. 2006;193(11):1478\u0026ndash;86.\u003c/li\u003e\n\u003cli\u003eMuzny CA KP. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sexually Transmitted Diseases. 2020;47(7):441\u0026ndash;6.\u003c/li\u003e\n\u003cli\u003eBilardi JE, Walker SM, Temple-Smith MJ, McNair RP, Mooney-Somers J, Vodstrcil LA, et al. Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis. PLoS One. 2017;12(3):e0173637.\u003c/li\u003e\n\u003cli\u003eAnstey Watkins J, Ross JDC, Thandi S, Brittain C, Kai J, Griffiths F. Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. PLoS One. 2019;14(11):e0224964.\u003c/li\u003e\n\u003cli\u003eNansel TR, Riggs MA, Yu K-F, Andrews WW, Schwebke JR, Klebanoff MA. The association of psychosocial stress and bacterial vaginosis in a longitudinal cohort. American Journal of Obstetrics and Gynecology. 2006;194(2):381\u0026ndash;7.\u003c/li\u003e\n\u003cli\u003eChetty C, Mafunda NA, Happel AU, Khan A, Demidkina BC, Yende-Zuma N, et al. Randomized Trial of Multi-Strain Lactobacillus crispatus Vaginal Live Biotherapeutic Products after Antibiotic Therapy for Bacterial Vaginosis: Study Protocol for VIBRANT (Vaginal Live Biotherapeutic RANdomized Trial). Preprint. 2025.\u003c/li\u003e\n\u003cli\u003eDeloitte, Datawheel. Data USA: Boston, MA. 2025. https://datausa.io/profile/geo/boston-ma/. Accessed 02 Sep 2025.\u003c/li\u003e\n\u003cli\u003eGeorge G, Beckett S, Cawood C, Khanyile D, Govender K, Kharsany AB. Impact of HIV testing and treatment services on risky sexual behaviour in the uMgungundlovu District, KwaZulu-Natal, South Africa: a cross-sectional study. AIDS Research and Therapy. 2019;16:20.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-womens-health","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmwh","sideBox":"Learn more about [BMC Women's Health](http://bmcwomenshealth.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmwh/default.aspx","title":"BMC Women's Health","twitterHandle":"","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Bacterial vaginosis, knowledge and attitudes, health seeking behaviour, vaginal hygiene, USA, South Africa, qualitative research","lastPublishedDoi":"10.21203/rs.3.rs-7516987/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7516987/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eBacterial vaginosis (BV), the most common cause of vaginitis among reproductive age women ,with, has high recurrence even after treatment. In addition to the physical risks of BV (e.g. increased HIV risk, adverse pregnancy outcomes, preterm birth), the symptoms (malodour, itchiness, vaginal discharge) can cause emotional impacts (e.g. shame, embarrassment, self-consciousness). BV knowledge, attitudes, behavioural change(s) after diagnosis and other previous vaginal health concerns were explored among participants in a clinical trial assessing the safety and biologic effects of a vaginal live biotherapeutic product.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003e In-depth interviews (IDIs) were conducted with female participants in a clinical trial in Boston, USA (n\u0026thinsp;=\u0026thinsp;14), and Vulindlela, South Africa (SA) (n\u0026thinsp;=\u0026thinsp;23). Interviews were audio recorded, transcribed and translated. Transcripts were coded and thematically analysed using NVivo.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003ePrevious BV diagnosis was lower in SA than USA (2(9%) versus 12(86%)), with 7(19%) overall reporting a previous STI. There were five key themes. (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e) Prior BV and other vaginal health experiences \u0026ndash; although BV was not frequently diagnosed in SA, participants reported experiencing symptoms (discharge, itchiness and malodour). Conversely, USA participants had experiences with previous BV diagnoses. (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e) Previous health seeking behaviour and treatments \u0026ndash; almost all participants from both sites had sought treatment from healthcare professionals for vaginal health concerns, with a few from both sites having used self-care practices. (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e) BV knowledge, attitudes and reactions to diagnosis \u0026ndash; BV knowledge in SA was poor compared with the USA, but most participants were relieved to receive help. (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e) Behavioural changes because of BV \u0026ndash; vaginal hygiene practices changed- participants washed more frequently/used products to address malodour. Further, BV symptoms resulted in changes in sex acts and/or abstinence. (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e) BV disclosure \u0026ndash; varied, with participants commonly disclosing to those who could provide them with support.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eBV knowledge, attitudes and experiences are related to previous diagnosis and treatment. Symptoms impact individuals\u0026rsquo; behaviours, regardless of previous diagnosis, and can have psychosocial impacts which need to be addressed via appropriate counselling and treatment strategies. Ongoing research for effective BV prevention, and treatment options that can be made available and accessible to women with BV globally, are needed.\u003c/p\u003e\u003ch2\u003eTrial registration:\u003c/h2\u003e\u003cp\u003eSouth African National Clinical Trials Registry (SANCTR DOH-27-102023-8342; October 27, 2023) and ClinicalTrials.gov (NCT06135974; November 02, 2023).\u003c/p\u003e","manuscriptTitle":"Bacterial Vaginosis [BV] knowledge, attitudes, and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: A qualitative study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-11 01:49:23","doi":"10.21203/rs.3.rs-7516987/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-13T23:17:10+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-13T19:26:07+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"138209670735269457752482134694752558163","date":"2025-10-13T12:50:55+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-12T15:04:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"289382920924590050484576830336139198859","date":"2025-10-07T04:09:31+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"44627246690551470963395832402815131829","date":"2025-10-05T19:57:30+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"257299354967876310438878928884714046869","date":"2025-10-02T05:31:15+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"335852632782932273353682056657172476179","date":"2025-09-30T15:02:18+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-09-29T20:30:49+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-29T12:52:57+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-09-09T12:18:34+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-04T12:19:39+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Women's Health","date":"2025-09-04T12:14:38+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-womens-health","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmwh","sideBox":"Learn more about [BMC Women's Health](http://bmcwomenshealth.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bmwh/default.aspx","title":"BMC Women's Health","twitterHandle":"","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2e1b1460-7339-45a5-85b8-ac845fa40d5b","owner":[],"postedDate":"October 11th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-12-15T16:05:54+00:00","versionOfRecord":{"articleIdentity":"rs-7516987","link":"https://doi.org/10.1186/s12905-025-04210-3","journal":{"identity":"bmc-womens-health","isVorOnly":false,"title":"BMC Women's Health"},"publishedOn":"2025-12-12 15:59:29","publishedOnDateReadable":"December 12th, 2025"},"versionCreatedAt":"2025-10-11 01:49:23","video":"","vorDoi":"10.1186/s12905-025-04210-3","vorDoiUrl":"https://doi.org/10.1186/s12905-025-04210-3","workflowStages":[]},"version":"v1","identity":"rs-7516987","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7516987","identity":"rs-7516987","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}